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Abbreviations 
 
APs   Action potentials 
BPI   Brief Pain Inventory 
CI   Confidence interval 
CNS   Central nervous system 
CRPS   Complex regional pain syndrome 
DBS   Deep brain stimulation 
DN4   Douluer Neuropatique en 4 questions 
DNIC   Diffuse noxious inhibitory control 
DREZ   Dorsal root entry zone 
DRG   Dorsal root ganglion 
DRGS  Dorsal root ganglion stimulation 
EEG   Electroencephalogram 
EFNS   European Federation of Neurological Societies 
EOG   Electrooculography 
EPs   Evoked potentials 
EQ-5D  EuroQol five dimensions questionnaire 
ERF   Emotional Role Functioning 
FBSS   Failed back surgery syndrome 
FDA   Food and Drug Administration 
fMRI   Functional magnetic resonance imaging 
GABA  Gamma-aminobutyric acid 
GHP   General Health Perception 
IASP   International Association for the Study of Pain 
ICD   International Classification of Diseases 
IMMPACT  Initiative on Methods, Measurement, and Pain Assessment in Clinical 
  Trials 
IPG   Implantable power generator 
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LANNS  Leeds Assessment of Neuropathic Pain 
LEPs   Laser-evoked potentials 
M0   Baseline measuring time-point with DRGS turned OFF 
M1  1-Month measuring time-point with DRGS turned ON 
M6  6-Months measuring time-point with DRGS turned ON  
MEG   Magnetoencephalography 
MH   Mental Health 
MRI   Magnetic resonance imaging 
NeuPSIG  Neuropathic Pain Special Interest Group 
NGFs   Nerve growth factors 
NPQ   Neuropathic Pain Questionnaire 
NRS   Numerical rating scale 
NS   Nociceptive specific 
P  Pain 
PDI   Pain Disability Index 
PeNS   Peripheral nerve stimulation 
PET   Positron emission tomography 
PF   Physical Functioning 
PLP   Phantom limb pain 
PNS   Peripheral nervous system 
PRF   Physical Role Functioning 
PSN   Primary sensory neurons 
QoL   Quality of life 
QST   Quantitative sensory testing 
RIII reflex  Nociceptive flexion reflex 
SCS   Spinal cord stimulation  
SEP   Somatosensory evoked potentials 
SF-36   Medical Outcomes Survey - Short Form 
SI   Primary somatosensory cortex 
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SII   Secondary somatosensory cortex 
SPECT  Single-photon emission computed tomography 
SRF   Social Role Functioning 
SSRs   Plantar sympathetic skin responses 
TENS   Transcutaneous electrical nerve stimulation 
TNF   Tumor necrosis factor 
V   Vitality 
VAS   Visual analog scale 
VRS   Verbal rating scale 
WDR   Wide dynamic range 
WHO   World Health Organization 
YAP  Yttrium - Aluminum - Perovskite 
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1 INTRODUCTION 
 
 
In this study, we used laser-evoked potentials (LEPs) to assess the efficacy of 
dorsal root ganglion stimulation (DRGS) as a treatment for chronic peripheral 
localized neuropathic pain. LEPs are considered the gold standard for the assessment 
of the functional integrity of pain pathways (Haanpaa, Attal et al. 2011). The 
mechanisms behind pain relief via electrical stimulation are not fully understood, and 
to the best of our knowledge, no study to date has used neurophysiological measures 
of pain perception in patients treated with DRGS.  
DRGS was introduced for clinical use in some European countries and in 
Australia in 2011. The therapy targets primary sensory neurons (PSN) within the 
dorsal root ganglion (DRG). Following peripheral nerve damage, glial cells, nerve 
growth factors (NGFs), ion channels, chemokines and specific genes in the DRG 
undergo several adaptive alterations (Krames 2014). How DRGS interferes with those 
mechanisms is still largely unknown.  
To investigate this issue, we performed the current prospective open-label 
study. At baseline (prior to DRGS therapy) and at one and six months after DRGS 
onset, the following variables were measured: LEPs parameters, pain intensity (using 
the Numerical Rating Scale, NRS), neuropathic pain components (using 
PainDETECT), quality of life  (using the Medical Outcomes Survey – short form, SF-
36) and pain disability (using the Pain Disability Index, PDI). A total of seven patients 
with localized neuropathic pain were enrolled in this study. All patients gave proper 
informed consent and only those who understood the study methods, and were able to 
regularly attend the experimental sessions were included.  
 
Therefore, this study had two main objectives: 1. To assess the efficacy of 
DRGS in pain management by measuring LEPs (taken to reflect pain pathways 
functional status) and NRS scores and 2. To correlate this treatment efficacy with 
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neuropathic pain components, quality of life and pain disability measurements, using 
the PainDETECT, SF-36 and PDI questionnaires, respectively.  
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2 BACKGROUND 
 
2.1 Pain 
2.1.1 Definition 
Pain is defined by the International Association for the Study of Pain (IASP) 
as an “unpleasant sensory and emotional experience with actual or potential tissue 
damage, or described in terms of such damage” (Loeser and Treede 2008). Others 
have defined it as a complex phenomenon, multidimensional in nature, an individual 
and subjective experience related to the person´s early life experiences involving 
beliefs, emotions and thoughts (Boos and Abebi 2008). Furthermore, nociception or 
pain perception comprises “the neural process of encoding and processing the pain 
stimulus, which is defined as an actual or potential event of tissue damage” (Loeser 
and Treede 2008). Nociception therefore enables an individual to elicit an 
appropriate, life-preserving reaction to a harmful stimulus (Thomas Cheng 2010) and 
thus avoid further lesions while protecting homeostasis. 
2.1.2 Pain classification 
Pain may be categorized in several ways. For treatment and research purposes, 
it is always judicious to fit a particular pain diagnosis into a specific group. In this 
regard, the most important aspects of pain are time course and type of pain. Having 
access to this information can help clinicians reach individualized diagnoses, thus 
optimizing the choice of therapy and treatment efficacy. 
2.1.2.1  Time course 
Pain may be classified as acute or chronic. Acute pain is commonly associated 
with ongoing tissue damage or a specific noxious stimulus that may occur following 
different pathophysiological scenarios such as infection or soft tissue lesions. Acute 
pain typically lasts for less than 1 month (Moore 2009) and serves as a physiological 
warning to the body of a specific threat or disease.  
The term “chronic pain” usually refers to pain that persists past the normal 
healing time (i.e. usually for more than 3 to 6 months; Treede, Rief et al. 2015) – in 
research, the most common standard is 6 months (Merskey, Bogduk et al. 1994). 
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During this longer time-period, pain has lost its function as a warning sign and 
becomes a disease.  
2.1.2.2 Types of pain 
Pain is commonly categorized into two main categories: nociceptive pain and 
neuropathic pain. Nociceptive pain arises from the activation of nociceptors (Loeser 
and Treede 2008) and can be subdivided into somatic and visceral nociceptive pain. 
Somatic nociceptive pain may in turn be categorized as either superficial or deep. 
Neuropathic, on the other hand, may be subdivided into central and peripheral 
neuropathic pain. Finally, the co-occurrence of nociceptive and neuropathic pain in 
the same patient is known as mixed pain (Baron and Binder 2004, Pazzaglia and 
Valeriani 2009). 
2.2 Neuropathic pain 
2.2.1  Definition 
The IASP originally defined neuropathic pain in 1994 as “pain initiated or 
caused by a primary lesion or dysfunction in the nervous system” (Merskey, Bogduk 
et al. 1994). Since then, this definition has been widely criticized for being too broad. 
In 2008, the definition was modified to “pain arising as a direct consequence of a 
lesion or disease affecting the somatosensory system” (Loeser and Treede 2008), 
which remains the currently accepted definition.  
2.2.2  Classification 
The most accepted classification of chronic pain is the one proposed by the 
World Health Organization (WHO) through the International Classification of 
Diseases (ICD). However, the latest released version, which is the 10th revision, does 
not reflect the current epidemiology of chronic pain, including chronic neuropathic 
pain. Therefore, an IASP task force developed a classification that will be released in 
the ICD-11. According to this new revision, there are four categories of neuropathic 
pain (Treede, Rief et al. 2015): 
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• Peripheral neuropathic pain 
• Central neuropathic pain 
• Other neuropathic pain 
• Neuropathic pain not otherwise specified 
In clinical practice, when a clear definition is not possible, one usually 
observes peripheral or central neuropathic pain. Peripheral neuropathic pain includes 
any disease or pathology affecting the peripheral nervous system (PNS; e.g. diabetic 
neuropathy), while central neuropathic pain comprises any disease or pathology 
involving the central nervous system (CNS; e.g. post-stroke pain) (Gilron, Jensen et 
al. 2013). Additionally, neuropathic pain is also classified as either spontaneous 
(stimulus-independent) or evoked (stimulus-dependent) (Pazzaglia and Valeriani 
2009). 
2.2.3 Diagnostic criteria 
A grading system for neuropathic pain diagnosis was released in 2008. The 
system proposes three levels of certainty by which neuropathic pain can be present or 
absent in an individual patient (possible, probable and definite neuropathic pain) (Fig. 
1). The use of such criteria helps stratify patients according to established methods of 
assessment and its use is recommended for clinical and research purposes. 
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Fig. 1 – Flow chart grading system for neuropathic pain (adapted from Treede, Jensen 
et al. 2008). 
 
2.2.4 Somatic representation 
In 2014, a screening tool based on the IASP grading system was developed to 
classify localized neuropathic pain and improve treatment strategies. When the area of 
maximum pain is circumscribed and smaller than a sheet of paper (A4 format), it was 
defined as localized neuropathic pain. If larger, it is considered neuropathic pain 
(Mick, Baron et al. 2014). However, sensitization mechanisms that typically occur in 
neuropathic pain are not accounted for in this screening tool.  
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Table 1 – Localized neuropathic pain screening questions (adapted from Mick, 
Baron et al. 2014). 
Question Observation 
• Does the patient’s history suggest a 
relevant nerve lesion or disease? 
 
• Is the pain distribution neuroanatomically 
plausible? 
 
• Does the neurological examination reveal 
any negative or positive sensory sign in the 
area of the presumably lesioned nerve? 
3x yes  = at least probable 
neuropathic pain 
• Is the most painful area circumscribed and 
smaller than an A4 paper? 
4x yes = at least probable 
localized neuropathic pain 
 
2.3 Dorsal root ganglion stimulation  
2.3.1 Background 
The electrical stimulation of neural targets for the treatment of chronic pain 
has been established for several decades. However, only recently have key structures 
associated with the physiological processing of pain signals been tested as potential 
therapeutic targets for neuromodulation. As the site of the first synaptic modulation in 
the pain pathway, the DRG is a key structure in pain processing. Despite its relation to 
the development of chronic pain, the DRG was not explored as a target for 
neuromodulative pain treatments until recent years. The first to attempt this approach 
were Wright and Colliton, who showed pain reduction by stimulating the DRG in one 
patient diagnosed with refractory discogenic low back pain (Wright and Colliton 
1998). In that case, the visual analog scale (VAS) score went from 8 to 2.5 after 8 
months of stimulation targeting bilateral DRGs at the L2 nerve root level.  
Nerve root stimulation attempting to recruit the DRG has also been shown to 
be beneficial (Alo, Yland et al. 1999), including stimulation using a transforaminal 
approach that resulted in effective pain relief (Haque and Winfree 2006; Kellner, 
Kellner et al. 2011). Additionally, a method for lead implantation with a curved stylet 
was shown to facilitate the procedure (Haque and Winfree 2009). In one case report, a 
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patient with post herpetic neuralgia in the left C2 dermatome did not require any 
medication following DRGS with an implanted peripheral nerve stimulation (PeNS) 
electrode (Lynch, McJunkin et al. 2011). No complications were described, and the 
stimulation effects remained stable over a 6-month follow-up period. Following the 
success of several single case reports and small series, DRGS should be further tested 
in larger groups of patients. With the recent design of a new specialized electrode, 
(Deer, Grigsby et al. 2013) DRGS has become more widespread. 
2.3.2 Anatomy and physiology of the dorsal root ganglion  
In humans, the dorsal root ganglia give rise to 31 pairs of nerves (8 cervical, 
12 thoracic, 5 lumbar, 5 sacral and 1 coccygeal) (Krames 2014). Proximally, the 
spinal nerves are divided into ventral motor efferent roots and dorsal sensory afferent 
roots. The dorsal root ganglia are localized in the dorsal root, close to the 
zygapophyseal joints and intervertebral disc (Fig. 2) (Hasegawa, An et al. 1993). As 
one moves caudally along the intervertebral foramen, the DRG becomes longer and 
wider. The positioning of the DRG shows little variability across subjects, and is 
located between the medial and lateral borders of the pedicles in most healthy 
individuals (Shen, Wang et al. 2006). Disease in adjacent structures can potentially 
cause compression and radiculopathy (e.g. herniated disc).  
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Fig. 2 – DRG anatomy. 
 
Reprinted from “Gray's Clinical Neuroanatomy – The Anatomic Basis for Clinical 
Neurosciences,” by Elliott L. Man and David G. Brock, 2011, Chapter 8, Spinal Cord 
and Nerve Roots, pg. 117. Copyright© 2011 by Saunders, an imprint of Elsevier Inc. 
 
The dorsal root ganglia contain almost all PSN cell bodies - as many as 15,000 
(Devor 1999). Because of the small size of the somata and the usually long axon, 
99.8% of the PSN cytoplasm is in the axon (Hogan 2010). The DRG therefore has 
high metabolic demand, with chemicals and proteins being transported over long 
distances.  
In DRG neurons, a single axon arises from the cell body and then divides into 
two branches, making them ‘pseudo-unipolar’. One branch extends peripherally and 
the other to the spinal cord, forming the so-called T-junction. This formation avoids 
information slowdown by the soma, thus ensuring fast action potentials (APs) 
transmission (Hogan 2010). The PSN in the DRG may also function as a low-pass 
filter to impulses coming from peripheral receptors (Krames 2014). 
In humans, DRG neurons are round and range in size between 20-150 µm. 
They are divided into two distinct types according to their cytoplasmic neurofilament 
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domains: large-light (type A) and small-dark (type B). Large-light neurons consist of 
myelinated Aß fibers while small dark neurons have Aδ and C fibers (Devor 1999). 
Within each DRG, there are several different cell populations, including cells that 
control sensory modality (heat, mechanical, chemical), range of sensitivity 
responsiveness, conduction velocity capability and neurotransmitter release 
specificity. Thus, the DRG is a highly specialized structure with several different 
neurophysiological functions (Hogan 2010). 
The surface of the DRG somata are covered by microvilli, which significantly 
increases the membrane surface (Devor 1999). Interestingly, the dorsal root ganglia 
have no blood-brain barrier, which allows the exchange of many small and large 
molecules, including drugs (Hogan 2010). However, although their surface 
membranes are permeable to many medications, they do not trap them within, thus 
lowering the chance of intoxication. Surrounding the soma are supporting satellite 
glial cells that regulate the neurons’ internal environment and maintain electrical 
isolation (Nedergaard, Ransom et al. 2003). Satellite cells also communicate with 
their associated soma. This configuration also limits interactions between 
neighbouring neurons, leading to non-synaptic coupling mechanisms that are 
responsible for cross-excitation (Devor 1999). According to Hanani, the satellite glial 
cells are similar to astrocytes, with some additional unique functions. The spatial 
configuration around the DRG allow for those satellite cells to exert tighter 
extracellular control relative to other glial cells, which also explains the absence of a 
blood-nerve barrier (Hanani 2005). 
The main function of PSNs is to conduct APs from the periphery to the CNS, 
but there is evidence that this also happens in the opposite direction (Hogan 2010).  
Ultimately, the role of the DRG neurons is to maintain a balanced membrane 
resting state, allowing for the correct interpretation of stimuli and ensuring 
appropriate responses during sensory encoding. During the APs, Na+, K+ and Ca2+ 
ions flow across the membranes ionic channels, leading to cell depolarization 
followed by repolarization. Ca2+ plays a special depolarizing role in these signaling 
mechanisms by entering the soma. Ca2+ also acts as second messenger in neuronal 
development, gene expression, neurotransmitter release, kinase activity and apoptosis. 
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Therefore, the proper functioning of the Ca2+ channels that are extensively distributed 
across the DRG membrane is of utmost importance (Abdulla and Smith 2001). 
2.3.3 Dorsal root ganglion stimulation - state of the art 
The development of a novel electrode system, specifically engineered for 
DRGS, has facilitated the use of this technique for the clinical treatment of chronic 
neuropathic pain. The electrodes used for DRGS are more delicate, smaller, thinner 
and more flexible than traditional spinal cord stimulation (SCS) electrodes. They can 
be percutaneously inserted, thus making the procedure minimally invasive (Bara and 
Deer 2016).  
One major potential advantage of DRGS is to complement traditional 
neuromodulation techniques such as SCS of the dorsal column. Initial observations 
indicate that DRGS is superior to conventional SCS for the treatment of localized 
pain, such as pain of the hand, individual fingers, the foot, the knee or the groin 
region. Moreover, SCS of the dorsal column commonly produces alterations in 
stimulation intensity or undesirable effects depending on body posture or movement 
pattern, which does not occur under DRGS (Kramer, Liem et al. 2015). Other 
problems related to traditional SCS include high lead migration rates with consequent 
loss of pain relief.  SCS may also cause unpleasant stimulation-associated paresthesia, 
and because it cannot accurately target smaller painful regions, these sensations are 
frequently generated in broader areas than the specific area of pain (Deer, Levy et al. 
2013b). DRGS may also help avoid such limitations.  
The first human study conducted with DRGS on 10 patients was published in 
2013 (Deer, Grigsby et al. 2013). In that study, DRGS was applied during a period of 
one week. Patients had been diagnosed with a neuropathic pain condition that was 
refractory to all previous therapies, either conservative or surgical. In this cohort, 
from the eight patients who completed the study, 75% experienced more than 50% 
pain relief relative to baseline, and all of them had anatomically specific relief over 
the painful region. Furthermore, medication intake was reduced by 78%. Also, pain 
ratings in the low back pain subgroup decreased by 84% after one week, a 34% higher 
rate than that observed in traditional SCS (North, Kidd et al. 2005). Finally, the 
authors were able to apply less electrical current with DRGS than is normally used for 
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SCS of the dorsal column, which saves battery life. The authors concluded that DRGS 
relieved pain in a satisfactory manner without any major safety concerns and 
highlighted the need for further corroborating studies.  
That publication was followed by the first prospective phase I multicenter 
study using DRGS (Liem, Russo et al. 2013). The main goals of that study were to 
analyze the rates of adverse events and paresthesias, as well as to evaluate pain relief, 
quality of life (QoL), mood and physical functioning. A total of 70 adverse events 
occurred in 24 of the 32 patients tested. Paresthesias due to stimulation were properly 
localized over the painful area and did not vary significantly with changes in body 
position. The overall average pain relief was 66% during the test phase and 56.3% at 
the 6-month end-point evaluation, at which time significant improvements in QoL, 
mood and physical functioning were also observed. During this trial, electrode 
migration rate was 3%, considerably lower than that observed in traditional SCS. The 
rate of pain reduction during the ON-phase of stimulation was always higher than 
50%. Foot pain, which is generally difficult to treat with traditional SCS, responded 
positively to DRGS. In conclusion, DRGS relieved chronic pain even in anatomical 
regions that are normally difficult to reach with SCS.  
The same group then published a 12-month follow-up study of the same 
population showing significant improved status in pain relief, mood and QoL (Liem, 
Russo et al. 2015). Thus, DRGS seems to be a better option for treating some 
neuropathic pain states, especially in cases of localized pain. However, the population 
studied by this group was heterogeneous in terms of neuropathic pain etiologies, 
which warrants further studies addressing specific pain conditions.  
Conventional SCS is a therapeutic option in patients with complex regional 
pain syndrome (CRPS) who do not respond to conservative clinical interventions (e.g. 
medication, physical therapy). However, Van Buyten et al. showed that DRGS can 
also be effective in treating this condition (Van Buyten, Smet et al. 2014).  
It is estimated that 2-4% of all patients who underwent herniorrhaphy will 
develop neuropathic pain as a consequence of nerve damage during surgery (Werner 
2014). Schu et al. studied the effectiveness of DRGS for localized neuropathic pain of 
the groin in 12 patients diagnosed with post herniorrhaphy pain (Schu, Gulve et al. 
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2014). An additional 17 patients presented with diverse etiologies involving chronic 
pain. Twenty-five of the 29 patients had a positive test trial and 23 of those completed 
the study protocol. Of the 23 patients, 82.6% had pain relief greater than 50%, as 
reflected in their VAS score. Therefore, also in the case of groin pain, DRGS provides 
pain relief that conventional SCS usually does not.  
The use of DRGS to treat phantom limb pain (PLP) was studied by Eldabe et 
al. (Eldabe, Burger et al. 2015). There is currently level IV evidence supporting the 
use of SCS to treat PLP, even though low rates of long-term pain relief have been 
reported (McAuley, van Groningen et al. 2013). SCS has been shown to be more 
effective against stump pain, which is often caused by a neuroma at the amputation 
nerve’s ending, and less effective against phantom phenomena or myofascial stump 
pain. These other conditions affecting amputated patients are very often neglected or 
co-occur in a single patient, rendering treatment in these cases challenging. Eldabe et 
al. investigated eight phantom-pain patients who received DRGS and reported an 
average pain reduction of 52% (Eldabe, Burger et al. 2015). The effects of DRGS in 
conditions such as visceral pain, somatic trunk pain and upper limb have yet to be 
determined (Liem 2015). 
2.4 Laser-evoked potentials  
2.4.1 Evoked potentials - definition 
Evoked potentials (EPs) reflect event-related electrical activity (i.e. the sum of 
excitatory and inhibitory post-synaptic potentials on cortical neurons) measured 
through electroencephalography (EEG) and represented as peaks and deflections. EPs 
are classified according to their time of occurrence in relation to the stimulus onset 
(latency), their polarity (negative or positive) and magnitude (amplitude). Thus, pain-
related EPs represent the neuronal response to a painful stimulus and may be used to 
detect and analyze neuronal function (Madsen, Finnerup et al. 2014). 
2.4.2 Background 
The use of laser radiant heat to selectively activate pain fibers in research was 
first described in 1975 (Mor and Carmon 1975). The first reports of such research 
employed CO2 laser, which is categorized in the infrared spectrum with a wavelength 
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of 10.6 µm. The total amount of energy delivered depends on the stimulus duration 
and laser beam diameter. The rate of CO2 laser skin reflectance is less than 2%, which 
is needed to elicit a clear cortical evoked response (Hardy 1980).  
In 1976, the same group used short laser pulses (in the ms range) that was 
locked to EEG recordings (Carmon, Mor et al. 1976). All subjects evoked highly 
similar responses after 20 to 50 averaged stimuli. The most prominent component was 
recorded from the Cz electrode linked to the earlobes and corresponded to a negative 
wave followed by a positive wave (Carmon, Mor et al. 1976). The greater the 
stimulus power, the larger the recorded peak-to-peak amplitudes. Notably, pain 
related potentials were produced only when individuals actually felt pain. Sensations 
of warmth that were not perceived as painful did not elicit a response.  
In 1978, the first study addressing the clinical significance of LEPs was 
published (Carmon, Dotan et al. 1978). There was a significant correlation between 
referred pain intensity and LEPs parameters. In fact, the authors concluded that the 
LEPs measured pain intensity objectively. LEPs amplitude correlated significantly 
with individuals’ pain rating scores. These results established LEPs as a 
neurophysiological correlate of pain experience (Carmon, Friedman et al. 1980). 
CO2 laser selectively activates thin and slow (C and Aδ) conduction fibers 
(Bromm and Treede 1984). A component analysis study showed that the late response 
originating from a stimulus on the left radial nerve dermatome elicited a negative-
positive wave over Cz against the ear lobes with latencies of 235 and 380 ms 
respectively, and a peak-to-peak amplitude of 16 µV (Bromm and Treede 1987). An 
ultra-late positive wave with amplitude of 8 µV was also recorded at about 1300 ms 
using a pressure block paradigm for Aß fibers. This approach resulted in two 
independent responses for two distinct patterns of pain sensations. The late 
component represented Aδ fiber activation (fast and sharp pain), whereas the ultra-
late component was related to C fiber activation (slow and dull pain). The late 
component was labeled N240/P370 and the ultra-late component was labeled 
N1050/P1250 (Bromm and Treede 1987). Yet another study identified four additional 
components: the N200, the P320, the N500, and the seldom-occurring P800 (Kakigi, 
Shibasaki et al. 1989). The greater the intensity of the subjective pain, the greater the 
amplitude of the P320 wave, which was maximal at the vertex. Tourniquet-induced 
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ischemia over the upper arm for 30 minutes gradually diminished the LEPs amplitude 
until it was no longer detectable. The lack of a signal correlated with the individual’s 
inability to rate the stimulus as painful. Also, after an anesthetic block was applied to 
the ulnar nerve, no pain sensation was experienced and therefore no LEPs were 
recorded. In that study, only Aδ waves were clearly identified. Importantly, no EPs 
were elicited after electrical or mechanical tactile stimulation. Therefore, the authors 
concluded that P320 LEPs reflect an evoked response specific to pain (Kakigi, 
Shibasaki et al. 1989).  
Arendt-Nielsen et al. tested healthy individuals to establish healthy thermal 
thresholds for use during laser stimulation. They considered skin thickness, 
temperature, color, sex and reflectance, as well as laser beam diameter and stimulus 
duration. Higher skin temperature was associated with lower pain thresholds.  
Increasing stimulus duration resulted in a logarithmic decrease in pain and sensory 
thresholds. Additionally, the smaller the beam diameter, the lower the pain or sensory 
threshold, as long as the power was kept constant. No pain threshold differences were 
observed for different skin pigmentations. Women had relatively lower pain 
thresholds, most likely due to their smaller skin thickness. Finally, intra-individual 
variability was low, suggesting robust results (Arendt-Nielsen and Bjerring 1988).  
Skin type also affects the threshold, with glabrous skin having a higher pain 
threshold relative to hairy skin. Thresholds also varied more within and across 
subjects with glabrous skin. Moreover, an increase in temperature in either skin type 
reduced the amount of energy needed to elicit any sensation (painful or non-painful). 
In conclusion, CO2 laser stimuli were found to selectively stimulate primary afferent 
fibers, including nociceptive receptors, thus eliciting painful as well as non-painful 
sensations (Pertovaara, Morrow et al. 1988). 
Currently, two main laser-evoked components are reliably recorded: the N1, 
which is a small-amplitude negative wave recorded in the temporal regions 
contralateral to the site of stimulation, and the N2/P2 biphasic complex the most 
studied component, which is maximal at the vertex and is the most reliable and 
reproducible measure across studies (Madsen, Finnerup et al. 2014)  (Fig. 3). 
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Fig. 3 – N2 and P2 LEPs components recorded in a healthy subject at our laboratory. 
 
2.5 Study aims 
 
It is known that the DRG plays a crucial role in pain processing. The DRG has 
traditionally been targeted to treat chronic neuropathic pain through ablative 
procedures, and has only recently been considered as a target for neuromodulation 
(Pope, Deer et al. 2013). Clinical results have shown that DRGS provides relief in 
some neuropathic pain conditions (Forget, Boyer et al. 2015). However, due to the 
recent introduction of this method, there is a need for new studies explaining these 
clinical effects. 
The current work had two main goals: to determine 1) whether DRGS-induced 
pain reduction correlates with LEPs measurements and 2) whether DRGS influences 
neuropathic pain components, QoL and disability related to chronic pain, as measured 
by different standardized tests.  
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2.6 Scientific questions 
 
 Hypothesis 1: DRGS restores the N2/P2 peak-to-peak amplitude in chronic 
neuropathic pain.  
Hypothesis 2: DRGS reduces chronic neuropathic pain and neuropathic pain 
components. 
 Hypothesis 3: DRGS improves QoL and disability related to chronic 
neuropathic pain.  
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3 MATERIAL AND METHODS 
 
3.1 Study design 
The study was performed prospectively and enrolled patients from the chronic pain 
outpatient clinic at the Department of Neurosurgery of the Eberhard-Karls University 
in Tuebingen, Germany. It was designed as a prospective, open-label non-placebo 
controlled study, with evaluation time-points at 1 and 6 months post DRGS. Patients 
were always aware of the stimulation of the painful area when DRGS was ON. DRGS 
produces paresthesia in the area corresponding to the specific nerve root dermatome. 
Medication intake was kept stable throughout the study. 
Inclusion Criteria 
• Patients > 18 years old 
• Confirmed diagnosis of localized chronic neuropathic pain, affecting only one 
side of the body, warranted by abnormal LEPs 
• Pain refractory to conventional medical treatment for at least 6 months 
• Confirmation of peripheral nerve or nerve root lesion (sensory loss, allodynia 
or motor deficits) 
• Normal cognition allowing understanding of the informed consent 
Exclusion Criteria 
• Prevalence of nociceptive pain 
• Psychosomatic pain and/or severe depression 
• Failure to comply with the study protocol or understand its terms 
• Skin lesion or disease in the area to be stimulated by the laser 
3.2 Dorsal root ganglion stimulation – surgical procedure 
During the first consultation with each patient, we noted the painful area, we 
determined the level of DRG to be treated based on the dermatome affected and in 
cases of clinical uncertainty, we conducted a test block using fluoroscopy. 
 22 
We also conducted routine pre-operative work-up assessments and patients 
were informed about surgical goals and risks in accordance with German Federal 
Law.  
Surgical Procedure 1 – Lead implantation 
The patient was taken to the operating room and the procedure was initiated 
under either general or local anesthesia. Local anesthesia is usually preferred because 
it allows patient’s neurological monitoring with greater precision. Intraoperative 
assessment also permits more accurate targeting. The patients were positioned on the 
operating table in a prone position with arms and pressure points securely cushioned. 
Kyphosation of the lumbar spine was performed to facilitate puncture of the epidural 
space. Patients’ skin was properly draped after iodine solution cleansing. Fluoroscopy 
in the antero-posterior view was then used to select the optimal needle entry point to 
best target the DRGS. We then placed the incision marks at the site designated for the 
implantable power generator (IPG), which is generally below the belt line around the 
buttock region. The needle entry point is located 1.5 to 2 levels below the intended 
interspinal space over the contralateral pedicle line. The needle tip should aim at the 
intended DRG at an angle of approximately 30 degrees relative to the anatomical 
spine midline. The epidural space was assessed using live-mode fluoroscopy guidance 
and the loss-of-resistance technique. After the puncture was made, its position was 
verified by inserting a flexible metallic guide-wire (Bara and Deer 2016).  
Then, a cylindrical quadripolar electrode (Spinal Modulation, Menlo Park, 
CA, USA) was prepared and introduced. This electrode is placed inside a sheath with 
a curved distal tip and secured to avoid sliding of the lead during navigation. The lead 
is navigated under fluoroscopy guidance into the neural foramen of interest. The 
optimal position is reached when the contacts are placed exactly below the pedicle, 
where the DRG is expected to be located. Lateral fluoroscopy is then performed to 
show the lead contacts, which are ideally located at the dorsal portion of the 
neuroforamen. Once optimal placement is achieved, the sheath is retracted carefully.  
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Fig. 4 – Schematic representation - DRGS at the thoracic (T12) DRG on the right 
side.  
 
Modified from original picture. Courtesy of St. Jude Medical – all rights reserved. 
Fig. 5 – Case example - DRGS leads placed at lumbar (L1 and L2) DRGs on the right 
side - postoperative radiographs in antero-posterior (A) and lateral (B) views.  
 
A lead strain relief loop in the epidural space is performed to avoid lead 
dislocation. Before retracting the needle, a subcutaneous pocket around the puncture 
site is created and the lumbar fascia is exposed. Next, the needle is completely 
retracted. An anchor device is inserted and at least two stitches with non-absorbable 
sutures are sewn and fixed to the fascia in order to avoid lead migration. A strain loop 
is created and placed in the subcutaneous pocket. The distal portion of the electrode is 
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then tunneled through the subcutaneous tissue and externalized through the skin on 
the lateral portion of the lumbar region. An impedance check is performed to verify 
the integrity of the electrical circuit and results should ideally range between 600 and 
1500 mΩ. Wound closure is performed on two layers. The externalized lead portion is 
secured to the skin with a suture and the wounds are draped with a sterile dressing.  
Test phase 
After surgery, the patient is taken to the ward and the leads are connected to an 
external power generator. Programming of the lead or leads is performed according to 
the patient’s response to different stimulation parameters. The aim is to cover the 
maximal possible area of pain to ensure satisfactory results. After optimal settings are 
set, stimulation is set to ON and the patient is discharged from the hospital on the next 
day to test the stimulation at home. Test stimulations are conducted for one week, 
after which the patient is evaluated in the outpatient clinic. If the response is 
considered positive (average pain relief of 50% or more compared to baseline 
according to NRS scores) and the patient is satisfied, we proceed to the IPG 
placement. The externalized leads are cut off in a sterile fashion and a suture is 
performed on the site of lead externalization to decrease risk of infection.  
Surgical procedure 2 – IPG implantation 
The patient is taken to the operation theatre and the procedure is performed 
under general anesthesia. The previously planned pocket site for the IPG is re-opened 
with blunt dissection to avoid breakage of the lead, which is often lying underneath 
the wound. After localizing the lead’s distal tips, an epifascial gluteal pocket is 
performed with blunt dissection, carefully controlling any bleeding with bipolar 
cautery. Once the opening is large enough to house the IPG, the leads are connected 
to the IPG ports and secured with a torque screwdriver system. Thereafter, the IPG is 
placed inside the pocket and two sutures are placed through the IPG fixation sites to 
the fascia in order to keep it in place, avoiding flipping or excess movement. The 
electrode impedances are re-checked through a remote controller. The closure is then 
performed in a three-layer fashion and the wound is draped with a sterile dressing.  
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Fig. 6 – IPG (Spinal Modulation, Menlo Park, CA, USA). Courtesy of St. Jude 
Medical – all rights reserved. 
 
Postoperative assessment 
After IPG implantation, the stimulation is turned to OFF. Two weeks after the 
termination of the test phase, chronic pain intensity has returned to baseline levels. At 
this time, the investigators explained the study to the patient and gave him/her the 
informed consent form to study and sign prior to enrollment.  
3.3 Enrollment and ethics 
The ethics committee of the University of Tuebingen approved the study under 
protocol number 096/2011BO2. Patients were enrolled in the study after 
understanding and signing the informed consent form and received no financial 
compensation for their participation. Participants were told that they could leave the 
study at any time without any consequences or alterations to their medical treatment.  
3.4 Functional assessment 
3.4.1 Clinical questionnaires 
On postoperative day 1 (M0), while the stimulation was still OFF, patients 
were asked to complete three different clinical questionnaires: 1) PainDETECT 
(Freynhagen, Baron et al. 2006), a neuropathic pain screening tool developed and 
validated in German, 2) SF-36, a self-report survey of patient QoL (Brazier, Harper et 
al. 1992), and 3) PDI, a validated tool to assess disability in chronic neuropathic pain 
(Tait, Pollard et al. 1987). The patients were given detailed instructions on how to fill 
out the questionnaires and were given two sets of blank questionnaire forms to take 
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home after discharge and to fill them out one day before returning for the remaining 
neurophysiological measurements (after 1 and 6 months, i.e. at times M1 and M6). 
3.4.2 Laser-evoked potentials  
Pre-measurement assessment 
On the morning of postoperative day 2, patients were recruited for LEPs 
recordings. Before leaving the ward, they were carefully instructed about the 
procedure, the risks, and the safety recommendations. The measurement workflow 
included the following steps, listed here in chronological order: 
• Patients were always admitted to the laboratory laser room during the 
morning, between 10:00 and 11:00 a.m. Then, he/she was asked to expose 
both legs and groins with underwear left on. Thereafter, the patient was asked 
to relax in a comfortable reclinable armchair.  
• The patient was then asked to indicate the site of maximal chronic pain, which 
we marked with a soft tip pen for the skin. This area was used throughout the 
study for all measurements and the contralateral homologous area was used as 
the control region. 
• Before measurements were taken, we used the NRS to determine each 
patient’s pain intensity. Next, we set up the EEG equipment, which is a 64 
Channel EEG system (ActiCap, BrainProducts, Gilching, Germany). The pain- 
evoked potentials were recorded using 32 channels, two additional channels 
were used for electro oculographic (EOG) recordings, and one other channel 
for offline re-referencing at the nose, for a total of 35 channels.  
• The equipment setup, which included two amplifiers, one power source, 
adequate cable connections, trigger port unit and a Microsoft Windows based 
EEG software - Brain Recorder version 2.0 (BrainProducts, Gilching, 
Germany), was mounted and set up following the manufacturer’s guidelines.  
• We measured the patient’s head perimeter with a centimeter scaled tape at the 
glabella-inion level in order to choose the appropriate EEG cap size (54, 56 or 
58 cm in diameter). This number was recorded and used in each patient’s 
subsequent experimental sessions. The electrodes were placed into the cap 
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following the 32-channel 10/20 system, using code numbers on each electrode 
as a guide.  
• We determined the Cz electrode’s position, which was at the intersection of 2 
lines: the glabella-inion and bitemporal line.  
• The cap and electrodes were then positioned using the Cz electrode as a 
reference and secured with a chin strap.  
• The three extra electrodes were placed using electrode-specific plastic holders 
and stickers to fix them appropriately: two on the epicanthal angle bilaterally 
for oculographic recordings and one at the nose.  
• The electrode sites were injected with special EEG conducting gel using a 
syringe with a blunt tip needle. The EEG system was then turned on to check 
for impedance. A light indicator at each electrode turns green when impedance 
is below 5 kΩ, which is considered optimal for data recordings. Impedance 
values were double-checked with the computer software after all lights turned 
green. 
• Patients and investigators wore laser protective goggles throughout the 
experiments.  
LEPs protocol 
• The measurements were performed with a CO2 laser device (MCO25, KLS 
Martin, Tuttlingen, Germany). A room was especially prepared in accordance 
with German regulations for class IV laser devices. The laser settings selected 
during the study were determined after extensive test sessions with healthy 
volunteers. The beam diameter was set to 3.5 mm and the laser pulse duration 
to 15 ms. These parameters were found to elicit a sharp, pinprick pain 
sensation without causing undesirable skin burns. 
• The first laser procedure was conducted to determine each subject’s pain 
threshold. Before beginning that session, we re-checked the side of pain and 
whether the stimulator was turned OFF (M0 measurement). The pain threshold 
was determined on the control area contralateral to the painful region. We 
assumed that because the pain was unilateral, no disease affected the non-
painful control region. Therefore, we were able to elicit normal LEPs from the 
control region, which functioned as a reference and internal control.  
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• Each participant received standardized instructions regarding the process of 
determining the pain threshold. They were told that the sensation should be 
similar to that of a drop of boiling water falling onto the skin (i.e. a sharp, fast, 
and slightly unpleasant painful sensation). We used an upward staircase design 
to detect each patient’s pain threshold: starting at low intensity laser power 
values, 3 laser pulses of each increasing laser power were subsequently 
delivered to the skin of the control region. When the sensation of sharp pain 
was elicited, after 3 consecutive laser shots, we recorded the value and set this 
as our NRS 4 score. This laser power value was recorded as the patient’s 
individual pain threshold and used throughout the whole experiment.  
• We used noise-cancelling in-ear earphones playing white noise to protect 
patients’ ears from the click produced by the laser device and to prevent any 
auditory-related potentials to create artifacts during the experiment. To this 
end, we performed three laser shots targeting the wall of the room while the 
white noise was playing. If the patient identified the click among the laser 
shots, we turned the volume up by 5% and retested until the white noise 
volume was loud so he/she could no longer perceive the clicks. That volume 
was then maintained constant during the whole experiment. 
• Before starting the experiment, we instructed patients to stay relaxed and to fix 
their gaze on a fixed point on the wall in front of them. They were asked to 
avoid blinking and any body movement during the recording sessions. To 
ensure patients were paying attention, we asked them to mentally count the 
number of laser shots perceived as painful during each block session and told 
them we would ask them at the end of the block how many shots they were 
able to feel.  
• The measurement session was designed in two parts. In the first part, we 
recorded LEPs from a dermatome on the control (non-painful) side to assure 
that the patient had understood the experiment and followed instructions. 
Whenever possible, LEPs were recorded from the L3 dermatome close to the 
medial portion of the skin next to the knee. If the L3 dermatome of the painful 
region was affected, we conducted the calibration on the dermatome above it. 
Twenty to 30 laser shots were delivered at this block session. During the 
measurement, the spot targeted by the laser beam was shifted slightly after 
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each shot to avoid habituation effects or repetitive stimulation of the same 
spot. We recorded the mean NRS score elicited by the whole set of laser shots. 
• In the second part of the experiment, we delivered one run of 20 to 30 laser 
shots with the laser power value set to match the previously determined pain 
threshold. The NRS score of the laser evoked pain sensation on the control 
region should be 4. The laser beam was moved slightly in between shots. First, 
the LEPs were recorded from the non-painful control side. As described 
above, we recorded the number of laser shots. We also made sure the NRS 
score was 4. The same procedure was then conducted for the painful side.  
• After the experiment, the DRGS was turned to ON. The patient was then 
released and instructed to keep the stimulation in the ON mode at all times.  
• After 1 month (M1) and 6 months (M6) of DRGS, the patient came back and 
repeated the experiment with the DRGS on the ON mode. 
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Fig. 7 – Study design. 
 
Fig. 8 – Experimental setup – LEPs protocol. 
 
 31 
Data processing and analysis 
EEG data were acquired at a 5000 Hz sampling rate and downsampled to 
500Hz. Continuous data were then band-pass filtered from 0.3 to 30Hz, segmented 
into epochs (-100 ms to 700 ms) and re-referenced to the nose electrode.   The EEG 
data were stored using codes created with Brain Recorder 2.0 (Brain Products, 
Gilching, Germany). Pre-processing was conducted using the Brain Analyzer version 
2.1 (Brain Products, Gilching, Germany). The time window of interest was selected 
based on the target component, the N2/P2 complex, which usually appears between 
150 and 450 ms after the onset of laser pulse. Baseline correction was performed from 
time window -100 ms to 0. We implemented an automatic artifact exclusion tool to 
discard epochs in the Cz channel exceeding ± 50 µV of amplitude. We then conducted 
a visual inspection and manually rejected any epochs contaminated with muscle or 
eye movement artifacts. Finally, the artifact free epochs from each trial were averaged 
and time-locked to the onset of the laser stimulus to measure Aδ-related LEPs. The 
N2 and P2 peaks in each curve were visually assigned according to the polarity, 
latency and scalp map. Whenever no evoked responses were detected from the painful 
side due to neuropathic pain, the N2 and P2 latencies of the LEPs recorded from the 
control side were used as references in the statistical analyses. The N2 and P2 peaks 
are maximal in amplitude at the vertex (Cz electrode) (Madsen, Finnerup et al. 2014). 
N2/P2 peak-to-peak amplitude from the Cz electrode data was measured using the 
Brain Analyzer 2.1 software. All data were recorded and stored in a Microsoft Excel 
worksheet file. 
3.4.3 Statistical analysis 
Background 
Statistical analyses were performed with the SPSS software, version 22 (IBM, 
USA). Our first goal was to evaluate the peak-to-peak amplitude of the N2/P2 LEPs 
and NRS scores before and after DRGS implementation, while our secondary goal 
was to investigate the effect of DRGS on neuropathic pain components, QoL and 
disability related to chronic neuropathic pain, as measured by the PainDETECT, SF-
36 and PDI clinical questionnaires. We used Friedman and Wilcoxon signed-rank 
tests for the first set of analyses (LEPs and NRS), and descriptive statistical methods 
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for the second set (PainDETECT, SF-36 and PDI). We used 95% confidence interval 
(CI) plots to show the peak-to-peak N2/P2 LEPs amplitude reproducibility on the 
control side. Data are summarized in box-plot and bar graphs. The significant alpha 
level was set at .05. Additionally, an alpha level Bonferroni correction was conducted 
before the first set of statistical analyses, for an alpha of .016. No further corrections 
were applied in the post-hoc analyses. 
Hypothesis 1 
We used the N2/P2 complex as a target for testing whether LEPs changes as a 
result of DRGS. We measured the N2/P2 complex’s peak-to-peak amplitude values in 
µV from the painful dermatome receiving DRGS and the homologous dermatome on 
the control non-painful side. We conducted descriptive statistics using a 95% CI error 
plot on the control non-painful side to assess the reproducibility of repeated recording 
sessions for the group data. We used the two-tailed Friedman test for repeated 
measures to compare all three data points. The level of significance was set at .016 
after Bonferroni correction.  If the test showed statistically significant results, the 
Wilcoxon signed-rank test was implemented for post-hoc comparisons between the 
three paired conditions.  
Hypothesis 2 
To test whether DRGS reduces chronic neuropathic pain, we applied two 
validated and standardized pain scales: the NRS, an 11-point self-report scale of pain 
intensity, and the PainDETECT, a screening questionnaire to identify neuropathic 
pain components. Due to the dataset’s small sample size and non-normal distribution, 
we compared scores at M0, M1 and M6 using the non-parametric Friedman test for 
repeated measures. The level of significance was set to .016 after Bonferroni 
correction. Whenever we observed statistically significant differences, we performed 
post-hoc analyses using the signed-rank Wilcoxon test to assess relationships between 
the three paired subgroups. PainDETECT questionnaire scores were descriptively 
assessed with box-plot charts. The graph depicts the mean scores that were classified 
according to the questionnaire’s cut-off limits (Fig. 14).   
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Hypothesis 3  
To assess whether DRGS affects QoL and disability related to chronic 
neuropathic pain, we used two validated and standardized clinical questionnaires: SF-
36 and PDI. We scored the SF-36 using the RAND score version (Hays, Sherbourne 
et al. 1993). Here again, we used descriptive statistics with box-plot and bar graphs.  
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4 RESULTS 
 
4.1 Demographic data 
Of the 16 patients recruited to participate in the study, seven completed all 
three time-point measurements and one was excluded due to predominantly 
nociceptive pain. Table 2 shows patient demographics: 
Table 2 – Study group demographics. 
Id Sex Age Pain 
duration 
(months) 
Etiology Area of Pain Levels 
Stimulated 
Side 
1 F 57 36 Post  femoral artery 
catheterism 
Groin L1 and L2 Right 
2 M 47 40 Post lumbar 
discectomy 
Groin and leg L2, L3 and L4 Right 
3 F 43 74 Post knee surgery Knee L3 and L4 Left 
4 M 53 120 Post lumbar 
discectomy 
Groin and leg L1 and L2 Left 
5 M 53 32 Post inguinal hernia 
surgery 
Groin L1 and L2 Right 
6 M 50 84 Post fracture 
correction surgery 
Leg L4 and L5 Right 
7 F 52 24 Post inguinal hernia 
surgery 
Groin L1 and L2 Right 
 
4.2 Laser-evoked potentials  
The N2/P2 peak-to-peak LEPs amplitudes were measured in µV at M0, M1 
and M6. On the non-painful control side, we performed a 95% CI graphical 
representation of the study group’s N2/P2 peak-to-peak amplitudes to show 
reproducibility (Fig. 9). On the graph one can observe that most amplitudes were 
between 10 and 17 µV across all measurements, with no statistical difference 
(Friedman Test, [χ2(2) = 2.000, p = .368]). The median values with interquartile 
ranges are 13.46 µV (11.61-16.33 µV), 14.16 µV (13.11-14.38 µV) and 13.59 µV 
(8.30-14.72 µV) at M0, M1 and M6, respectively. 
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Fig. 9 – 95% CI N2/P2 peak-to-peak amplitude (µV) from the non-painful control 
side, showing reproducibility across measurements at M0, M1 and M6. 
 
A two-tailed non-parametric Friedman test for repeated measures revealed a 
significant effect of DRGS on the N2/P2 peak-to-peak amplitudes [χ2(2) = 10.571,    p 
< .01]. A Wilcoxon signed-rank test showed that the amplitudes at M0 were different 
from M1 [Z = -2.366, p < .05] and M6 [Z = -2.366, p < .05], showing a significant 
increase of the N2/P2 peak-to-peak amplitude after implementation of DRGS (Fig. 
10). 
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Fig. 10 – N2/P2 peak-to-peak amplitude (µV) on the painful side significantly 
increased at M1 and M6 in comparison to M0. 
 
We then calculated the grand average of the seven patients’ N2/P2 EEG 
curves. Figure 11 shows a graph with the data from all three time points overlayed, 
which shows restoration of the peak-to-peak amplitude after DRGS at M1 and M6 in 
comparison to M0. 
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Fig. 11 – Grand average LEPs curves (n=7), showing no LEPs at M0 and LEPs 
restoration at M1 and M6. 
 
Next, a two-tailed non-parametric Friedman test for repeated measures 
revealed a significant effect of DRGS on the ratio of peak-to-peak amplitudes 
between the painful test side and the non-painful control side [χ2 (2) = 11.143, p < 
.01]. The Wilcoxon signed-rank test showed that the ratio at M0 was different from 
M1 [Z = -2.366, p < .05] and M6 [Z = -2.366, p < .05]. The significant increase from 
M1 to M6 indicates LEPs restoration to near normal levels (Fig. 12). 
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Fig. 12 – Ratios of the N2/P2 peak-to-peak amplitudes (µV) of the painful versus non-
painful side, showing a significant increase in the M1 and M6 ratio relative to M0. 
 
4.3 Pain intensity evaluation 
NRS scores were significantly lower under DRGS (Friedman Test, [χ2(2) = 
11.385, p < .01]): Scores at M1 [Z = -2.371, p < .05] and M6 [Z = -2.371, p < .05] 
differed significantly from those at M0 (Wilcoxon signed-rank test; Fig. 13).  
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Fig. 13 – NRS scores significantly decreased at M1 and M6 in comparison to M0. 
 
The mean values of spontaneous pain intensity in the affected area decreased 
from 7.6 at baseline to 2.1 at 1 month and 2.2 at 6 months after introduction of DRGS. 
This corresponds to an overall NRS pain score decrease of 73% at 1 month and 72% 
at 6 months.  
4.4 Neuropathic pain components 
Mean PainDETECT values decreased from 19.7 at M0 to 15.7 at M1 and 14.5 
at M6. Interestingly, scores decreased in line with pre-defined cut-off values, which 
divide score ranges into 3 distinct intervals (neuropathic, unclear and nociceptive) 
(Fig. 14). This finding indicates neuropathic pain amelioration. 
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Fig. 14 – PainDETECT scores decreased at M1 and M6 relative to M0. 
 
4.5 Quality of life assessment 
The SF-36 is organized into eight different QoL dimensions: Vitality (V), 
Physical Functioning (PF), Pain (P), General Health Perceptions (GHP), Physical 
Role Functioning (PRF), Emotional Role Functioning (ERF), Social Role Functioning 
(SRF) and Mental Health (MH). Each dimension is scored on a scale of 0 (worst QoL) 
to 100 (best QoL) (Fig. 15).  
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Fig. 15 – SF-36 mean scores on 6 out of 8 items improved at M1 and M6 relative to 
M0.  
 
Only two of the dimensions showed no improvement over time: General 
Health Perceptions and Emotional Role Functioning. By contrast, the mean score for 
Pain went from 22.5 at M0 to 43.2 at M1 and 52.5 at M6 (Table 3).  
Table 3 – Mean SF-36 scores. 
 M0 M1 M6 
V 38.5 53.5 54.2 
PF 42.8 62.1 58.5 
P 22.5 43.2 52.5 
GHP 57.8 44.2 53.5 
PRF 25.0 50.0 53.5 
ERF 71.4 66.6 71.4 
SRF 46.4 62.5 69.6 
MH 56 66.8 66.8 
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4.6 Pain-related disability assessment 
PDI scores range from 0 (no disability related to pain) to 70. Scores decreased 
at M1 (22.8) and M6 (18) relative to M0 (38.5; Fig. 16). 
Fig. 16 – PDI scores decreased at M1 and M6 in comparison to M0. 
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5 DISCUSSION 
 
5.1 Neuromodulation for pain - background 
The use of electrical stimulation to treat pain conditions dates to 15 A.D., 
when accidental contact with a torpedo fish resulted in relief from gout pain 
(Goldenberg 2006). In the modern era of medicine, pain neuromodulation arose after 
the publication of the gate control theory by Melzack and Wall in 1965 (Melzack and 
Wall 1965). Two years later, Shealy et al. published the first description of electrical 
stimulation of the spinal cord by insertion of a lead in the subarachnoid space of the 
dorsal column to treat a cancer pain patient (Shealy, Mortimer et al. 1967). Thereafter, 
the first commercially available spinal cord stimulator system was released in 1968 
(Kumar and Rizvi 2014). Since then, the field of neuromodulation for pain, especially 
SCS, has evolved exponentially. Research in the area of neuromodulation continues to 
elucidate the mechanisms behind this technique and contribute to its improvement. 
Research using evidence-based together with mechanism-based medicine can 
contribute to the development of state-of-the-art treatments (Levy 2012).  
Several studies addressing the effects of neuromodulation on different pain 
conditions have been published during the last decade (Boswell, Shah et al. 2005, 
Airaksinen, Brox et al. 2006, Boswell, Trescot et al. 2007, Cruccu, Aziz et al. 2007, 
North, Shipley et al. 2007, Manchikanti, Boswell et al. 2009, Manchikanti, Abdi et al. 
2013). Most of those studies focused on SCS systems with the usual electrode design 
specifications engineered to be inserted into the dorsal column. In those studies, the 
frequency of stimulation was set at a regularly spaced, fixed rate of electrical spikes, 
mostly between 30 and 300 Hz (Meier 2014). This is typically called tonic SCS of the 
dorsal column.  
In a recent review of neuromodulation for the treatment of chronic pain 
including SCS (Deer, Krames et al. 2014), the authors suggested that more 
randomized studies testing efficacy are needed, and also that efforts should be made 
to guarantee patients’ access to such techniques. Furthermore, they recommended 
consensus meetings be held to determine the most appropriate use of neurostimulation 
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for pain. According to Meier, 25 to 50% of patients do not benefit from SCS (Meier 
2014), and several authors have suggested ways of producing better outcomes 
(Sindou, Mertens et al. 2003, Atkinson, Sundaraj et al. 2011, Campbell, Jamison et al. 
2013). Currently, the only clear positive level of evidence (I to II) for tonic low-
frequency SCS of the dorsal column is for patients diagnosed with failed back surgery 
syndrome (FBSS) (Grider, Manchikanti et al. 2016; Manchikanti, Falco et al. 2014).  
5.2 Innovative approaches using spinal cord stimulation 
SCS has been used now for nearly half a century. However, there is still plenty 
of room for design innovations, system upgrades or hardware/software refinements. 
There have been several recent advancements in this area, particularly for SCS. These 
include rechargeable generators, multicolumn electrode leads, long-range telemetry, 
self-adjustable stimulation, magnetic resonance imaging (MRI) compatible systems, 
wireless rechargeable leads, novel programming waveforms, and electrodes for new 
stimulation targets. Some technologies expected to emerge in the near future are new 
stimulation paradigms, closed loop stimulation, optogenetic-based stimulation, the 
addition of neurochemicals to hybrid systems and miniaturization (Slavin 2014). The 
techniques with the greatest impact on clinical practice are most likely the two new 
waveform programming paradigms available for SCS, high frequency stimulation and 
burst stimulation, and DRGS (Raja & Wallace 2015).  
5.2.1 Electrical properties of the stimuli 
Relative to traditional (tonic) SCS, burst and high frequency SCS stimulation 
have been shown to offer better clinical outcomes (De Ridder, Plazier et al. 2013, 
Kapural, Yu et al. 2015). Burst stimulation is set to 40 Hz burst mode as  a constant 
stimulus with 5 spikes at 500 Hz per burst and pulse width with interspike intervals of 
1 ms, while high frequency stimulation consists of SCS at regular spaced spikes of 
stimulation with frequencies of up to 10 kHz (Raja & Wallace, 2015). Clinical trials 
using both techniques have shown preliminary positive results, including pain relief 
without paresthesia generation, particularly for lower back pain (Tiede, Brown et al. 
2013, Al-Kaisy, Van Buyten et al. 2014, de Vos, Bom et al. 2014, Schu, Slotty et al. 
2014, Kapural, Yu et al. 2015). A recent review article gave level of evidence IV for 
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burst stimulation and level of evidence II to III for high frequency stimulation.  
(Grider, Manchikanti et al. 2016).  
5.2.2 Dorsal root ganglion stimulation  
DRGS for the treatment of chronic pain is a relatively recent technique (Deer, 
Grigsby et al. 2013). Since 2011, DRGS is performed in some European countries and 
in Australia (Deer, Kramer et al. 2014). Some studies have referred to the technique 
with a different name: “spinal cord stimulation of the dorsal root ganglion” (Liem, 
Russo et al. 2015). Most authors agree that DRGS recruits the CNS (Liem 2015). A 
recent review highlights DRGS as an emerging management option for neuropathic 
pain (Pessoa, Escudeiro et al. 2015). Additionally, contemporary textbooks in the 
field of neuromodulation have already dedicated an exclusive chapter to DRGS for 
the treatment of chronic pain (Kugler 2013, Knotkova and Rasche 2014, Deer and 
Pope 2015, Slavin 2015).  
A recent review suggested, that despite some evidence for the efficiency of 
DRGS, that more evidence is needed of its long-term efficacy and safety (Forget, 
Boyer et al. 2015). These authors further recommended the use of tools such as LEPs 
and quantitative sensory testing (QST) (Forget, Boyer et al. 2015). The ACCURATE 
study is a large ongoing clinical trial that aims to evaluate the safety and effectiveness 
of DRGS for patients diagnosed with CRPS I and II (2016). In it, a group receiving 
DRGS is compared to a control group receiving traditional tonic SCS. Follow-up 
results at 12 months have been positive. Relative to the control group, more patients 
who received DRGS reported successful pain relief (74.2% vs. 53% of patients). 
Additionally, most DRGS patients had better stimulation targeting, enabling better 
coverage of the painful area. There was also a lower rate of paresthesia in the 
stimulated area among the DRGS patients (2015). As a result of these findings, in 
February 2016, the Food and Drug Administration (FDA) approved the treatment with 
DRGS for patients diagnosed with CRPS type I and II in the United States. It is 
important to note that this clinical trial was sponsored by the manufacturer of the 
neuromodulation system, raising a potential conflict of interest. 
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5.3 Mechanisms of action of neuromodulation  
5.3.1 Background 
Although neuromodulation was introduced several years ago, the mechanisms 
underlying the treatment of chronic pain through it have yet to be fully understood. 
But before understanding the mechanics behind SCS and even DRGS, one must fully 
understand neuropathic pain pathophysiology. In the following sections, we also 
consider the standardized methods used to quantify results, such as pain intensity 
scales, neuropathic pain assessment tools, and neurophysiological techniques.  
5.3.2 Pathophysiology of chronic neuropathic pain  
Chronic neuropathic pain is defined as maladaptive pain resulting from a 
lesion or disease affecting the somatosensory system. In contrast to regular pain, 
which plays a protective role in avoiding further tissue damage, chronic neuropathic 
pain offers no biological function. Neuropathic pain syndromes usually present a 
combination of negative symptoms or sensory deficits (e.g. loss of sensation), 
together with positive symptoms, which may include paresthesia or allodynia (Woolf 
and Mannion 1999). The diverse clinical presentation in neuropathic pain is directly 
related to the variety of mechanisms responsible for chronic pain development, 
including ectopic neuronal activity due to hyperexcitability, peripheral sensitization 
associated with a reduced activation threshold of the PSN, central sensitization due to 
increased excitability and synaptic efficacy of neurons in central nociceptive 
pathways, impaired inhibitory mechanisms of nociception, and activation of microglia 
and other non-neural cells in the CNS (Table 4) (Gilron, Jensen et al. 2013, Gilron, 
Baron et al. 2015).  
 47 
Table 4 – Neuropathic pain mechanisms (modified from Gilron, Baron et al. 2015). 
Neuropathic pain mechanisms 
• Ectopic activity 
• Peripheral sensitization 
• Central sensitization 
• Impaired inhibitory modulation 
• Activation of microglia 
Several chronic pain mechanisms are generated in the spinal cord, the first 
relay in the pain pathways from the periphery to the brain (D'Mello and Dickenson 
2008).  There are currently two possible distinct theories regarding chronic pain: 
central sensitization (i.e. neurogenic hyperalgesia), which manifests as slight sensory 
loss and partial nociceptive deafferentation (i.e. painful hypoalgesia), which presents 
as significant sensory deficits (Baumgartner, Magerl et al. 2002). Identifying the 
sensory profile of an individual’s neuropathic pain can lead to better selection of 
therapy, which highlights the importance of a mechanism-based classification of 
neuropathic pain (Baumgartner, Magerl et al. 2002, Cruccu and Truini 2009).   
5.3.3 Peripheral neuropathic pain  
In this brief review, we focus on the pathophysiological mechanisms of 
peripheral neuropathic pain, which is defined as “pain arising as a direct consequence 
of a lesion or disease affecting the peripheral somatosensory system” (Loeser and 
Treede 2008). Peripheral neuropathic pain manifests as spontaneous, stimulus-
independent pain and/or as stimulus-evoked pain  (i.e. pain hypersensitivity) (Fig. 17) 
(Woolf and Mannion 1999). Peripheral nerve damage can lead to significant 
alterations in the neuron itself and/or in processes involved in nociception. Finally, a 
peripheral nerve lesion can lead to a number of pathophysiological alterations (Kehlet, 
Jensen et al. 2006).  
Spontaneous and evoked pain 
Spontaneous pain is often described as shooting, lancinating or burning pain. It 
can be further divided into paroxysmal pain and constant pain. Paroxysmal pain is 
associated with high frequency bursts generated ectopically. Not only are the 
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peripheral terminals sensitized, but also the cell bodies and the region near the DRG, 
contributing to the generation of spontaneous bursts (Truini and Cruccu 2006). On the 
other hand, constant pain is the most typical form of neuropathic pain, and is 
attributed to either spontaneous firing of C fiber afferents due to excitation of C 
nociceptors in the skin, or as a consequence of central hyperactivity resulting from 
deafferentation.  
Evoked pain is also a common outcome in peripheral neuropathic pain and 
may manifest as hyperalgesia or allodynia. Hyperalgesia is defined as “increased pain 
sensitivity” (Loeser and Treede 2008), generally resulting from abnormal processing 
of nociceptor input. Neuropathic hyperalgesia can be categorized as primary or 
secondary. Primary hyperalgesia is caused by the sensitization of the injured tissue 
after a peripheral nerve lesion, whereas secondary hyperalgesia is produced in an 
adjacent portion of unaffected tissue in response to CNS sensitization (Cohen and 
Mao 2014). Allodynia, on the other hand, is defined as “pain in response to a non-
nociceptive stimulus” (Loeser and Treede 2008). It is believed that allodynia 
translates a pure sensitization of the peripheral receptors, with reduction of the 
mechanical threshold in the sensitized nociceptors (Serra 1999). However, the most 
accepted explanation contends that central nociceptive neurons are sensitized to 
mechanically evoked input mediated by Aß fibers (Truini and Cruccu 2006). 
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Fig. 17 – Aetiology, mechanisms and symptoms of peripheral neuropathic pain 
(modified from Woolf and Mannion 1999). 
 
5.3.4 Pathophysiology of the dorsal root ganglion in neuropathic pain 
The DRG is a key structure in the processing of pain in chronic pain states, 
affecting intricate mechanisms in peripheral and central pain processing. The DRG 
participates in various pain-related pathophysiological modifications during 
inflammation, somatic pain and neuropathic pain. In a recent review, the authors 
suggest that the DRG is an important therapeutic target in the treatment of 
neuropathic pain and also the source of mechanisms associated with the development 
of neuropathic pain (Sapunar, Kostic et al. 2012). In the event of nerve injury, the 
PSN in the DRG start to generate ectopic discharges, contributing to neuropathic pain 
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and paresteshias (Wall and Devor 1983, Amir, Michaelis et al. 1999, Sapunar, 
Ljubkovic et al. 2005). Membrane potential oscillations at sub-threshold levels are 
increased in a chronic nerve injury and are associated to the ectopic discharges in the 
DRG (Amir, Michaelis et al. 1999). The ectopic activity is thought to be the source of 
pain producing signals after peripheral nerve lesions (Truini, Biasiotta et al. 2010). It 
is also known that the DRG starts to respond to blood-borne chemicals following a 
nerve lesion (Burchiel 1984). 
One of the mechanisms responsible for hyperexcitability is thought to be the 
loss of Ca2+ influx into the somata (Lirk, Poroli et al. 2008). It has been shown that 
loss of Ca2+ current is related to the passage of high-frequency bursts from the 
periphery to the CNS. Furthermore, the low-pass filtering function that ensues in 
healthy DRG neuronal cells on the T-junction is impaired (Luscher, Streit et al. 1994). 
Some pathological conditions, such as neural injury and increased neural activity, 
may decrease the concentration of extracellular Ca2+. This often happens following a 
nerve injury, which enhances hyperexcitability even when ion channel properties are 
not affected (Lirk, Poroli et al. 2008).  
After a nerve lesion, the neural activity of the DRG is intensely modulated by 
a complex cascade of immune and glial cell responses (Scholz and Woolf 2007). The 
release of signaling inflammatory molecules from these cell types can lead to 
hypersensitivity of nociceptors in the periphery (Julius and Basbaum 2001). 
Following a peripheral nerve injury or inflammation, the glial cells surrounding the 
soma proliferate. Those cells produce cytokines and neurotropins, which in turn 
contribute to chronic pain states (Znaor, Lovric et al. 2007), and the release of 
neurotropic factors has been shown to exacerbate allodynia (Zhou, Deng et al. 2000). 
Nerve growth factor, a neurotropin that is elevated in inflammatory tissues, can 
modify PSN phenotype, altering sensory neuron function and leading to persistent 
pain (Woolf 1996). 
Inflammatory cell proliferation surrounding the DRG after nerve injury 
involves macrophages and lymphocytes (Hu and McLachlan 2002). As these cells 
release excitatory cytokines, generation of ectopic neuron firing ensues, leading to 
neuropathic pain development (Hu and McLachlan 2002). It has been shown that 
tumor necrosis factor (TNF) alpha, a pro-inflammatory cytokine, can induce neuron 
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ectopic activity (Sorkin, Xiao et al. 1997). Additionally, inflammation at the level of 
the DRG is important in the development of neuropathic pain (Li, Xie et al. 2011). 
Na+ ion channels are associated with increased excitability in DRG C cells. An 
enhancement of C cell excitability has been shown after nerve injury in rats, which 
was most likely associated with a Na+ channel mechanism (Zhang, Donnelly et al. 
1997). Also, after axotomy, there is an up-regulation of type 3 sodium channel 
mRNA, which is not normally expressed by mature DRG neurons, and this may 
explain Na+ channel involvement in hyperexcitable states after nerve injury (Waxman, 
Kocsis et al. 1994). Lower APs thresholds in DRG neurons with an increase in 
spontaneous APs were also observed in a study analyzing rats after ligation of the 
sciatic nerve, suggesting that the DRG cell body is the source of this abnormal 
activity (Study and Kral 1996). It is reasonable to assume that the pathological 
activity in the DRG may be associated with the initial phases of neuropathic pain 
(Wall and Devor 1983). Neuropathic pain hyperexcitability has also been linked to 
Na+ channel hyper-expression (Devor, Govrin-Lippmann et al. 1993).  
K+ channels are also involved in neuropathic pain development, as seen in a 
rat model of sciatic nerve injury (Kajander, Wakisaka et al. 1992). Furthermore, 
alterations in K+-channel function have been associated with chronic pain, including 
neuropathic pain (Du and Gamper 2013). Moreover, impairment of glial K+ 
homeostasis may further contribute to pain (Takeda, Takahashi et al. 2011). 
Norepinephrine, an excitatory neurotransmitter, can alter DRG physiology due 
to the DRG’s sympathetic sensitivity in chronic pain states. Norepinephrine 
sensitivity can lead the PSN in the DRG to develop spontaneous firing. Moreover, 
after a nerve injury, norepinephrine appears to influence neuronal firing of sensitized 
A and C fibers via up-regulated alfa2-adrenoceptors, especially when there is ongoing 
spontaneous neuron activity. The abnormal sympathetic neuronal activity may be 
associated with cutaneous pain and hyperalgesia (Xie, Zhang et al. 1995). Finally, 
sympathetic innervation of the DRG after nerve lesions may play a role in 
sympathetically maintained neuropathic pain (Chung, Lee et al. 1996). 
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5.3.5 Spinal cord stimulation of the dorsal column - mechanisms of action  
Gate control theory  
The gate control theory proposed by Melzack and Wall was the most accepted 
theoretical framework explaining pain relief during SCS of the dorsal column 
(Melzack and Wall 1965). According to this model, a “gate” acts as an integrative 
center mediated by A fibers. The stimulation of the dorsal column leading to 
activation of A fibers can activate inhibitory interneurons in the dorsal horn. 
Interneuron activation, in turn, suppresses pain transmission by “closing” the gate to 
the afferent nociceptive inputs generated by small myelinated Aδ or unmyelinated C 
fibers. In order to validate this model as a mechanistic explanation, SCS must 
suppress the activity of wide dynamic range (WDR) neurons and SCS-mediated 
inhibitions must involve inhibitory interneurons (Zhang, Janik et al. 2014). Some 
evidence in rats points to a drastic reduction in the WDR neurons’ spontaneous 
activity rate in the dorsal root following a conditioned stimulus in the dorsal column 
or in the posterior root (Guan, Wacnik et al. 2010). Additionally, pain suppression in 
animal models of neuropathic pain under SCS has been shown through suppression of 
WDR neurons, which requires activation of A-fibres originating from the pain area 
(Guan 2012). Dorsal horn WDR hyperexcitablity has been shown to normalize after 
SCS (Yakhnitsa, Linderoth et al. 1999).  
Segmental mechanisms 
With the publication of additional potential segmental mechanisms explaining 
pain relief during SCS, the gate control theory was considered to be insufficient on its 
own. The gate theory fails to fully explain SCS mechanisms of action (Kumar, Toth et 
al. 1998), and this view is corroborated by clinical findings of sustained pain relief 
even after cessation of stimulation (Lindblom and Meyerson 1975). For example, 
electrical stimulation of low-threshold afferents in an area surrounding the primary 
excitatory receptive field of a neuron results in inhibition of the neuron, similarly to 
stimulation of the dorsal column (Hillman and Wall 1969), and is therefore based on a 
mechanism similar to SCS. The influence of different cell populations, such as 
nociceptive-specific (NS) neurons and low-threshold neurons within the dorsal horn, 
can additionally influence pain relief during SCS. Distinct roles of these cells as well 
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as the interaction with the WDR neurons led to the development of the hypothesis of a 
microcircuit of pain perception (Prescott and Rate 2012). Furthermore, additional 
segmental effects include aberrant nerve sprouting into atypical laminae following a 
nerve lesion (Woolf, Shortland et al. 1992), excitatory synaptic receptor expression 
leading to hyperexcitability and sensitization of NS neurons (von Hehn, Baron et al. 
2012), and loss of inhibitory mechanisms (Woolf and Wall 1982), all of which are also 
not accounted for by the gate theory (Zhang, Janik et al. 2014). The SCS-induced 
WDR neuron inhibition can occur to a greater extent if the electrode is positioned at 
the spinal level adjacent to the affected dermatome, and this suggests a segmental 
spinal site of action (Smits, van Kleef et al. 2012). Gamma-aminobutyric acid 
(GABA) mediated inhibition of local interneurons appears to be the driver of A-fiber 
mediated inhibition (Zhang, Janik et al. 2014), which also seems to be segmental. 
This GABA mediated effect was demonstrated in two clinical randomized trials 
through use of GABA B receptor agonist baclofen (Lind, Schechtmann et al. 2008, 
Schechtmann, Lind et al. 2010). 
Supraspinal mechanisms 
Supraspinal mechanisms appear to be independent of segmental mechanisms 
and may play a role in SCS (Saade´, Tabet et al. 1986, Foreman and Linderoth 2012). 
Opioidergic (Sato, King et al. 2013), serotoninergic (5-HT) (Song, Ultenius et al. 
2009), adenosinergic (Cui, Sollevi et al. 1997) and cholinergic (Schechtmann, Song et 
al. 2008) systems have also been shown to contribute to SCS, and recent evidence in 
rats suggests modulation of a spinal-supraspinal loop (Song, Ansah et al. 2013). The 
nucleous raphes magnus in the rostroventromedial medulla (Song, Ansah et al. 2013) 
and periaqueductal gray matter (Sorkin, McAdoo et al. 1993) appear to contribute to 
the descending antinociceptive system in SCS. Inhibition of neuropathic pain in rats 
has been shown to occur through dorsal column stimulation by activation of brainstem 
centers via rostral projections of the dorsal column nuclei (El-Khoury, Hawwa et al. 
2002). It is possible that SCS pain relief may be a consequence of a complex 
interaction between ascending and descending fibers as well as due to direct root 
stimulation (Yang, Carteret et al. 2011). In fact, spinal and supraspinal mechanisms 
appear to be acting synergistically in pain relief through SCS (Barchini, 
Tchachaghian et al. 2012). 
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Finally, changes in the pain matrix (i.e. the network of brain areas involved in 
pain processing) also contribute to SCS-mediated pain relief (Tracey and Mantyh 
2007; Garcia-Larrea and Peyron 2013). Researchers have identified areas of 
activation and/or inhibition of dorsal column nuclei which may function as a neural 
relay for SCS-induced alterations in the brain (Qin, Yang et al. 2009). Studies using 
functional magnetic resonance imaging (fMRI) showed increased activation of 
primary somatosensory cortex (SI) and secondary somatosensory cortex (SII) during 
neuropathic pain (Kiriakopoulos, Tasker et al. 1997), and pain reduction by SCS has 
been associated with reduced activity in prefrontal cortex, cingulate gyrus, thalamus, 
supplementary motor area, and postcentral gyrus (Rasche, Siebert et al. , Moens, 
Sunaert et al. 2012). Moreover, the effects of activation due to SCS in the 
contralateral insula and ipsilateral SII following unilateral painful heat stimulation 
were higher when measured during simultaneous stimulation (SCS + heat evoked 
pain) than when measured separately under either SCS or heat evoked pain. This 
finding raised the hypothesis that SCS interferes with pain processing by saturating 
neuronal circuits with neuronal impulses, which in turn reduces input to the pain 
matrix (Stančák, Kozák et al. 2008).  
A positron emission tomography (PET) study in patients undergoing SCS for 
angina showed a number of regions (i.e. medial prefrontal cortex and cingulate gyrus) 
associated with nociception (Hautvast, Ter Horst et al. 1997). Another PET study 
showed significant simultaneous activation of the contralateral thalamus and bilateral 
parietal association area, as well as activation of the prefrontal cortex and cingulate 
gyrus during SCS, suggesting a strong influence of multiple supratentorial structures 
in pain processing (Kishima, Saitoh et al. 2010). And another PET study by Sufianov 
et al. showed that patients under SCS experience a normalization of brain metabolism 
and function (Sufianov, Shapkin et al. 2014). Further neuronal activation/deactivation 
patterns in multiple brain regions were also found in a Tc-99m-HMPAO single-
photon emission computed tomography (SPECT) study (Nagamachi, Fujita et al. 
2006).  The identification of lateral and medial pain systems related to distinct 
noxious and innocuous CO2 laser stimuli confirmed a major division of function 
within the pain matrix (Kulkarni, Bentley et al. 2005), and both may be affected by 
SCS, especially in the new waveform paradigm of burst (De Ridder, Plazier et al. 
2013). Although studies have shown pain matrix effects after SCS, several authors 
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believe that few conclusions can be drawn and that more studies are necessary to 
assess the specific role of each particular brain area (Meier 2014, Zhang, Janik et al. 
2014).  
To conclude, there remains an incomplete understanding of SCS mechanisms 
of action and chronic neuropathic pain response to this technique. Thus, there is a 
wide opportunity for further research towards new experimental models and clinical 
investigation, as well as to explore novelty stimulation paradigms (Meier 2014, 
Bentley, Duarte et al. 2016). 
5.3.6 Dorsal root ganglion stimulation -  proposed mechanisms of action 
Most studies on DRGS to date include PSN cultured cell techniques, 
neurophysiological assessment or animal models.  
The neuronal somata of the first sensory neurons lie within the DRG, 
including those conveying Aδ and C fibers. Spontaneous or facilitated firing of 
lowered threshold neurons in the DRG can produce hyperexcitability, increasing pain 
signals towards the spinal cord. The mechanism behind pain alleviation through 
DRGS can be elucidated from research with electrical deep brain stimulation (DBS) 
(McIntyre, Savasta et al. 2004). Similarly to DBS, DRGS could potentially alter 
abnormal electrical activity of DRG neurons, decreasing pain by modulating ion 
channels through use of external electrical current (Bradford 1970). Specific genes 
that alter neuronal function are also expressed under electrical stimuli (Klein, Tendi et 
al. 2003). Evidence from cultured DRG cells show a direct correlation between 
electrical DRGS and neuronal somata activation (Fuchs, Rigaud et al. 2007). Yet 
another study recently showed that field electrical stimulation of DRG neurons can 
cause Ca2+ influx, triggering second messenger processes. Ca2+ enhanced influx has 
been associated to decreased excitability and restored the filtration of high-frequency 
action potentials (Koopmeiners, Mueller et al. 2013).  
Electrical stimulation of neural tissue was shown to stimulate the synthesis of 
growth factors. There is evidence that electrical DRGS may release abnormal growth 
factors and/or inhibit the release of normal ones (Aaron, Boyan et al. 2004). Similar 
 56 
mechanisms may be extended to immune response changes, which would lead to 
decreased pain following electrical DRGS.  
As seen following dorsal column stimulation, autonomic effects are observed 
after electrical DRGS, which suggests that the dorsal root afferent fibers influence 
downstream autonomic effects (Croom, Foreman et al. 1997). Proposed mechanisms 
of DRGS based on this assumption include vasodilatory effects. Additionally, one 
may expect stabilization of nociceptors in the periphery, deactivation of WDR 
neurons in the dorsal horn and modulation of supraspinal brain regions involved in 
chronic pain (Krames 2015). Another hypothesis proposes that DRGS has a potential 
effect on DRG microglia, decreasing the release of chemokines associated to chronic 
pain, as seen in DBS (Vedam-Mai, van Battum et al. 2012). The decrease of the pro-
inflammatory effect on microglia has been shown with electrical stimulation in a rat 
photic injury model (Zhou, Ni et al. 2012).  
Table 5 – Hypothesized mechanisms of action - DRGS (modified from Krames 2015). 
Hypothesized mechanisms of action  - DRGS 
• Modification of growth factor release 
• Reversal of cytokine release 
• Downstream and upstream effects 
• Rectification of electrical activity patterns 
• Reversal of genetic changes 
• Down-regulation of abnormal ion channels and restitution of normal ion 
flux 
• Filtering of electrical impulses 
According to Yan et al., DRG electrical stimulation leads to nerve 
regeneration with neurite outgrowth via calcium influx that may result in stabilization 
of pain neurophysiology (Yan, Liu et al. 2014), a mechanism that has also been 
modeled computationally (Adams, Willits et al. 2016).  
In sum, DRGS may function as a signal stabilizer of pain input coming from 
the periphery. Furthermore, it may reverse neural plasticity and sensitization of the 
CNS or even prevent maladaptative changes if initiated early in neuropathic pain 
patients (Liem 2015). 
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5.3.7 Neurophysiological assessment under neuromodulative therapies  
Neurophysiological tools such as somatosensory evoked potentials (SEP), 
plantar sympathetic skin responses (SSRs), F-wave, H-reflex, nociceptive flexion 
assessment (RIII-reflex) (de Andrade, Bendib et al. 2010), have allowed investigators 
to further test SCS mechanisms of action in real clinical practice. In a study with 
FBSS patients, the authors assessed a variety of neurophysiological measurements 
during SCS ON and OFF conditions: segmental spinal integration was measured by 
means of sensorimotor reflexes for small fibers (RIII-reflex) and large fibers (H-
reflex); spinal motorneuron excitability was assessed by recording F-waves; 
suprasegmental sensory pathways (dorsal columns) were examined by recording P40-
SEP; and SSRs were assessed to evaluate SCS effects on sympathetic-related activity. 
Normalization of neurophysiological values during the ON condition were found in 
SSRs, F-wave persistence, reduced F-wave amplitude, increased F-wave latency and 
increased SEP latency. Significant differences between ON and OFF were found in 
SEP amplitude, H-reflex amplitude, RIII-reflex threshold and RIII-reflex area (de 
Andrade, Bendib et al. 2010).  
Other studies have also found attenuation in RIII-reflex after SCS (Garcia-
Larrea, Sindou et al. 1989, Garcia-Larrea, Peyron et al. 2000), which may be the 
strongest objective evidence of a real analgesic effect. A decrease in P40-SEP 
amplitude speaks in favor of supraspinal mechanisms effect (de Andrade, Bendib et 
al. 2010, Larson, Sances et al. 1974, Doerr, Krainick et al. 1978). A collision of 
action potentials travelling in opposite directions on peripheral large diameter fibers 
may explain such findings (Buonocore, Bodini et al. 2012). Antidromic action 
potentials as well as orthodromic activation of supraspinal systems may act 
simultaneously to relieve pain in SCS (Weigel, Capelle et al. 2015). Median and 
posterior tibial nerve SEP attenuation of abnormally enhanced responses was 
observed in patients under SCS for neuropathic pain (Theuvenet, Dunajski et al. 
1999). The SEP amplitude decrease was also shown in a more recent study and was 
greater in SCS when compared to transcutaneuos electrical nerve stimulation (TENS) 
(Wolter, Kieselbach et al. 2013). 
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During SCS ON, attenuation of somatosensory processing in SI and SII was 
also observed during SEP of the tibial and sural nerve using a high density EEG 
dipole reconstruction method. The tonic increase of SI and SII cortical activity due to 
SCS-related lemniscal neuron activation or the inhibition of somatosensory afferent 
input at the segmental level is thought to diminish sensitivity to neuropathic pain 
(Polacek, Kozak et al. 2007). Enhancement of plantar SSRs reveals that there is also a 
sympathetic effect (de Andrade, Bendib et al. 2010). Bilateral decrease in pain 
threshold after cessation of SCS on a population diagnosed with unilateral pain speaks 
in favor of the supraspinal effects of SCS. Moreover, SCS appears to adjust the 
neurophysiological response of the neuropathic pain side to the unaffected side 
(Weigel, Capelle et al. 2015).  
In conclusion, these findings suggest an inhibition of Aß and Aδ myelinated 
fibers either at a segmental or suprasegmental level, as well as provide objective 
evidence of pain relief during the SCS ON condition (de Andrade, Bendib et al. 
2010). Taken together, the neurophysiological data suggest that SCS normalizes 
pathological pain processing in chronic pain patients to a more healthy state of 
cortical activity (Bentley, Duarte et al. 2016). 
5.4 Laser-evoked potentials  
 
Laser-evoked potentials (LEPs) are the gold standard assessment tool to 
evaluate pain physiology and pathophysiological mechanisms (Bromm and Lorenz 
1998, Haanpaa, Attal et al. 2011). LEPs can be used to investigate specific diseases 
that affect the nociceptive system (Treede, Meier et al. 1988, Kakigi, Shibasaki et al. 
1990, Bromm, Frieling et al. 1991, Treede, Lankers et al. 1991, Kakigi, Kuroda et al. 
1992, Agostino, Cruccu et al. 2000, Cruccu, Leandri et al. 2001, Garcia-Larrea, 
Convers et al. 2002, Spiegel, Hansen et al. 2003, Truini, Haanpaa et al. 2003). 
Furthermore, solid-state lasers (e.g. Neodymium Yttrium - Aluminum – Perovskite 
(YAP)) facilitated application to any body region and also decreased unintended 
superficial skin burns (Spiegel, Hansen et al. 2000, Cruccu, Pennisi et al. 2003).  
In 2004, the European Federation of Neurological Societies (EFNS) released 
guidelines for neuropathic pain assessment (Cruccu, Anand et al. 2004). At the time 
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of the publication, LEPs studies amounted to little more than 100 scientific articles in 
peer-reviewed journals. The expert panel review stated that LEPs were the most 
reliable neurophysiological tool to assess the functional integrity of nociceptive 
pathways and granted a grade B level of recommendation for use of Aδ LEPs to 
diagnose peripheral and central neuropathic pain. A grading system proposed to 
diagnose neuropathic pain in clinical and research scenarios has included LEPs as one 
of the principal tests, reinforcing its relevance in neuropathic pain investigation 
(Treede, Jensen et al. 2008). LEPs detect any functional conduction abnormality in 
the pain pathways, even when caused by minute somatosensory system lesions 
(Cruccu, Aminoff et al. 2008). LEPs should be included in the standard treatment of 
patients diagnosed with painful disorders, particularly in situations where the clinical 
sensory tests are inconclusive or the causative illness is unclear (Haanpaa, Backonja 
et al. 2009, Pazzaglia and Valeriani 2009).  
A revision of the 2004 guidelines from the EFNS published in 2010 showed a 
substantial new number of high quality studies on LEP (Lefaucheur and Creange 
2004, Truini, Galeotti et al. 2008, Truini, Padua et al. 2009, Haanpaa, Attal et al. 
2011), upgrading the level of recommendation of LEPs to grade A (Cruccu, Sommer 
et al. 2010). LEPs were also shown to be a good option to monitor and evaluate pain-
related conditions in the elderly who show degenerative changes in the nociceptive 
pathways (Cruccu and Truini 2010). A second separate revision published in 2011 by 
the Neuropathic Pain Special Interest Group (NeuPSIG) also issued a level A grade of 
recommendation for the use of LEPs to assess Aδ fiber pathways in neuropathic pain 
(Haanpaa, Attal et al. 2011).  
More recently, Garcia-Larrea proposed that a “physiological photograph” with 
the use of neurofunctional methods such as LEPs is highly relevant, prompting 
optimized management strategies (Garcia-Larrea 2012). Definite diagnosis of 
neuropathic pain yields at least one objective confirmatory test proving existence of 
lesion or disease affecting the somatosensory system (Treede, Jensen et al. 2008); and 
LEPs can determine better than any other tool such an impairment. The author 
suggests that abnormal LEPs elicited from a painful region should be interpreted as an 
electrophysiological signature of neuropathic pain (Garcia-Larrea 2012). A study by 
Valeriani et al. also recently highlighted LEPs role in identifying the underlying 
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pathophysiological mechanisms of neuropathic pain subtypes (Valeriani, Pazzaglia et 
al. 2012). 
In conclusion, the LEPs technique is to date the most advanced and reliable 
method to evaluate the functional integrity of pain pathways, and can also be used to 
study pain sensation and modulation (Matre and Nilsen 2014, La Cesa, Tamburin et 
al. 2015, Mainka, Maier et al. 2015). 
5.4.1 Effects of dorsal root ganglion stimulation on laser-evoked potentials 
LEPs precisely identify lesions in any portion of the nociceptive system. Laser 
pulses through CO2 laser or solid-state lasers (thulium or neodymium-based) 
exclusively activate Aδ and C fibers while avoiding the activation of Aβ non-
nociceptive related fibers.  
Functional assessment of the nociceptive pathways is of utmost importance 
during the management of neuropathic pain patients (Valeriani, Pazzaglia et al. 
2012). It is established that neuropathic pain arises from nociceptive pathway damage 
(Truini, Garcia-Larrea et al. 2013). In our study, we used the CO2 laser, which is the 
most widely used in clinical investigation. The fact that we observed a clear LEP 
alteration in comparison to a control non-painful area in our study confirms that our 
patients had a definitive localized neuropathic pain (Mick, Baron et al. 2014, Treede, 
Jensen et al. 2008). When no pathologic condition affects the pain pathways, LEPs 
should reflect the functional integrity of the nociceptive system. Suppression, reduced 
amplitude or delayed latency of LEPs in comparison to a valid control is considered a 
hallmark in substantiating the diagnosis of neuropathic pain (Valeriani, Pazzaglia et 
al. 2012).  
In this study, we selected patients with unilateral pain, thus allowing the 
internal control to be performed on the homologous contralateral non-painful region. 
Spontaneous pain is often associated to complete absence of LEPs, whereas provoked 
pain signs such as allodynia/hyperalgesia may show partially preserved LEPs (Truini, 
Biasiotta et al. 2010). In our study group, some patients showed complete abolition of 
LEPs at baseline, while others showed a decreased peak-to-peak amplitude response 
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compared to controls. Positive signs such as allodynia or hyperalgesia were not 
directly associated with partially preserved LEPs.  
As mentioned above, LEPs reliably reflect Aδ fiber activation. The so-called 
N2/P2 complex, the component most frequently evaluated in clinical practice, 
represents activation of insular networks and the anterior cingulate cortex, with some 
contribution from prefrontal and parietal regions, reaching maximal amplitudes at the 
vertex. Aδ-related LEPs have also demonstrated good intra-subject reproducibility, 
making it an ideal tool for a repeated measures study design (Bentley, Youell et al. 
2002, Garcia-Larrea 2006). In our group, we observed inter-session reproducibility in 
the control condition, which reinforces the findings of our test condition. The N2 
response is considered to be a more reliable measure of the nociceptive volley, as it is 
less influenced by cognitive or attention effects (Garcia-Larrea 2012). In fact, LEPs 
are a mixture of sensory and attentional-cognitive responses and should be interpreted 
as such. To improve inter-session reproducibility, attentional levels should be kept 
stable across measurements (Garcia-Larrea 2006). In our study, we instructed 
patients to keep their eyes open and to count the stimuli to keep attentional levels as 
constant as possible.  
When neuropathic pain affects only one or a few dermatomes, LEPs 
accurately detect the area of disease. These dermatome-guided LEPs facilitate 
measurements in localized neuropathic pain (Lorenz, Hansen et al. 1996, Quante, 
Hauck et al. 2007).  
In our study group, we selected the most painful area inside a dermatome 
territory. This is important, since the stimulated area is also dermatome-guided, which 
ensures we are eliciting responses from the correct region. Paresthesia over the 
painful region also confirms that we have selected an appropriate region to test.  
SCS of the dorsal column as well as DRGS alleviate pain. It is hypothesized 
that the DRG may be an extension of the CNS, and as a consequence a laterally 
displaced portion of the spinal cord (Liem 2015). In line with this theory, one may 
also hypothesize that some mechanisms by which DRGS decreases pain may be 
shared with those attributed to traditional SCS of the dorsal column. However, DRG 
is a promising target for modulation because it represents the first integration stage 
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along the pain pathways. Moreover, some mechanisms may be exclusive to DRGS 
(Krames 2015).  
To the best of our knowledge, only one published article has studied LEPs in 
patients under SCS of the dorsal column and no study has reproduced such findings 
using DRGS (Sestito, Lanza et al. 2008). In that article, patients diagnosed with 
cardiac syndrome X and treated with SCS showed a significant increase in N2/P2 
peak-to-peak LEP amplitudes during stimulation ON in comparison with stimulation 
OFF. This finding is in line with our results: after DRGS, we observed a significant 
increase in the N2/P2 peak-to-peak LEP amplitude elicited from the most painful area 
of chronic neuropathic pain after 1 and 6 months of ON stimulation in comparison 
with baseline (OFF).   
One possible explanation for an increase in LEP amplitude is that just as in 
traditional SCS, DRGS removes the inhibition caused by sustained chronic pain, 
known as diffuse noxious inhibitory control (DNIC). DNIC can selectively inhibit the 
convergent neurons in the dorsal horn of the spinal cord during sustained noxious 
stimuli. This mechanism is even more pronounced when high frequency APs are fired 
(as occurs in the DRG during neuropathic pain), thus amplifying the effect by 
temporal summation (Le Bars, Dickenson et al. 1979). LEPs may also be affected by 
chronic neuropathic spontaneous pain acting as a heterotopic-like pain stimulus. We 
hypothesize that spontaneous continuous chronic pain could actually function as an 
overload of neuronal input leading to painful evoked-response signal disruption. This 
concept was confirmed in humans with CO2 laser stimuli, corroborating a counter-
irritation mechanism following a painful stimulus, which decreased VAS ratings of 
laser-evoked painful stimuli in normal subjects (Kakigi 1994).  
As a complement to DNIC, DRGS inhibition of PSN hyperexcitablity 
synergistically amplifies pain alleviation. Spontaneous or facilitated firing of lowered 
threshold DRG neurons in neuropathic pain conditions can substantially increase pain 
signals in the direction of the spinal cord. Electrical DRGS has been shown to 
modulate ion channels, restore the filtration of high-frequency APs and activate DRG 
somata (Bradford 1970, Fuchs, Rigaud et al. 2007, Koopmeiners, Mueller et al. 
2013). We hypothesize that DRGS can function by decreasing the excessive 
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discharges caused by the DRG hyperexcitable neurons in neuropathic pain, thereby 
restoring the functional integrity of pain pathways. Ultimately, this could lead to the 
normalization of cortical processing, as suggested by our findings.  
It is known that precise synchronous neuronal firing is essential for normal 
APs transmission. One of the roles of the DRG is to function as a low pass filter and 
to modulate electrical impulses from the nociceptors to the dorsal root entry zone 
(DREZ) (Gemes, Koopmeiners et al. 2013). Pain relief may be a consequence of the 
restoration of the high-frequency action potentials filtering in the DRG (Liem 2015). 
Here, chronic spontaneous pain inhibited acute laser-evoked pain, as reflected by 
LEPs. In fact, LEPs abnormalities may reflect a lesion on the thermo-algesic 
transmission and not the pain per se. Therefore, the restoration of pain pathways 
during DRGS may explain the LEP amplitude increase (Garcia-Larrea 2012). 
As suggested by previous work, the electrode’s position is of critical 
importance to optimize pain relief. In a study testing SCS in rats, placing the lead 
contacts at the level where the damaged fibers reach the dorsal horn resulted in 
superior pain relief than placing them rostrally to the lesion (Smits, van Kleef et al. 
2012).  
Moreover, SCS of the dorsal column can regularly activate cutaneous afferents 
via the dorsal root (Buonocore, Bonezzi et al. 2008). Dorsal root stimulation has been 
associated with pain relief and has been shown to decrease WDR neuronal 
spontaneous activity in the dorsal horn to a similar degree as dorsal column 
stimulation (Guan, Wacnik et al. 2010). In line with this finding, we hypothesize that 
the DRG may play a role during dorsal root stimulation, explaining, at least partially, 
the pain relieving effect of decreasing the spontaneous activity of WDR neurons.  
Magnetoencephalograpy (MEG) has also been used to record evoked 
potentials during SCS for chronic neuropathic pain. A small study reported restoration 
of SI organization after tactile-evoked responses in two patients receiving SCS for 
CRPS (Pahapill and Zhang 2014).  
In summary, LEP serves as an objective measure of DRGS efficacy for 
chronic peripheral localized neuropathic pain. The restoration of N2/P2 peak-to-peak 
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LEPs amplitudes suggests a normalization of the pain signal transmission through the 
thermo-algesic pathways and a normalization of pain processing at the cortical level. 
5.5 Pain intensity assessment 
The visual analog scale (VAS), numerical rating scale (NRS) and verbal rating 
scales (VRS) are the most commonly used pain scales in the literature (Haanpaa, 
Attal et al. 2011). A systematic review concluded that NRS is superior to VAS and 
VRS and recommends standardization based on the NRS-11 (Hjermstad, Fayers et al. 
2011). Also, recent neuropathic pain guidelines graded NRS as level A 
recommendation for pain intensity measurement (Haanpaa, Attal et al. 2011).  
To measure pain intensity, the patient is asked to assign a number between 0 
and 10 that best represents the pain intensity he or she is experiencing. ‘0’ means no 
pain and ‘10’ is the worst possible pain. As ongoing burning pain is the most typical 
type of pain associated with neuropathic pain (Marchettini 2005), the NRS is one of 
the primary outcome measures in this work.  
5.5.1 Effects of dorsal root ganglion stimulation on pain intensity  
In our group of seven patients there was a significant decrease in NRS pain 
scores in comparison to baseline after one and six months of DRGS. The mean values 
of spontaneous pain intensity in the affected area decreased from 7.6 at baseline to 2.1 
at 1 month and 2.2 at 6 months after introduction of DRGS. This corresponds to an 
overall NRS pain score decrease of 73% at 1 month and 72% at 6 months and is in 
accordance with the published data in the literature (Liem, Russo et al. 2013).  
Deer et al. reported 70% overall pain reduction in VAS scores after a pilot 
study to evaluate the short-term safety and effectiveness of DRGS (Deer, Grigsby et 
al. 2013). Similarly, Liem et al. reported 58% overall pain reduction in VAS scores at 
the 6-month follow-up in a group of 32 patients treated with DRGS for various 
chronic pain etiologies (Liem, Russo et al. 2013). At the one-year follow-up, 
published two years later, overall pain was still reduced by 56% (Liem, Russo et al. 
2015).  
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Other studies evaluating single etiology neuropathic pain patients also showed 
positive pain relief outcomes using DRGS. Schu et al. reported an overall pain 
reduction of 71.4% in VAS scores in a study with 25 patients managed with DRGS 
for chronic groin pain after a mean follow-up of 42.5 months (Schu, Gulve et al. 
2014). Similarly, Van Buyten et al. reported 62% overall pain reduction in a study 
with eight patients diagnosed with CRPS (Van Buyten, Smet et al. 2014). Eldabe et al. 
reported 50.8% in overall pain reduction in VAS scores in a study addressing 
phantom limb pain after a mean follow-up of 14.4 months (Eldabe, Burger et al. 
2015). Single case reports, although using different electrode designs, also showed 
positive results (Lynch, McJunkin et al. 2011, Garg and Danesh 2015).  
Another important measurement is the rate of patients who experience more 
than 50% pain relief after DRGS. In our group, five out of seven patients (71%) had at 
least 50% pain relief at both the 1 and 6 month follow-ups. This finding is also in line 
with the literature, which reports rates between 60 and 82% (Deer, Grigsby et al. 
2013, Liem, Russo et al. 2013, Schu, Gulve et al. 2014, Van Buyten, Smet et al. 2014, 
Liem, Russo et al. 2015). Moreover, these rates of pain relief are better than results 
reported in studies with traditional SCS of the dorsal column, which are between 40-
50% for radicular pain. 
5.6 Neuropathic pain screening tools 
The aim of the neuropathic pain screening tools is to identify neuropathic pain 
for clinical or research purposes (Haanpaa, Attal et al. 2011). These tools consist of 
standardized questionnaires designed to recognize pain characteristics associated with 
neuropathic pain. In comparison to one-dimensional pain scales such as the NRS-11, 
neuropathic pain screening tools assess neuropathic pain syndromes in greater detail. 
Identifying neuropathic pain is important to select the right therapy, including 
neuromodulation. Pain descriptors included in such questionnaires are considered to 
have a discriminant diagnostic value (Bouhassira and Attal 2011). The 5 validated 
screening tools recommended by recent guidelines include the Leeds Assessment of 
Neuropathic Pain Symptoms and Signs (LANNS), Douleur Neuropatique en 4 
questions (DN4), Neuropathic Pain Questionnaire (NPQ), ID Pain and painDETECT 
(Haanpaa, Attal et al. 2011). Overall, these tools fail to indicate the correct diagnosis 
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in 10 to 20% of patients with clinically diagnosed neuropathic pain (Bouhassira and 
Attal 2011).  
5.6.1 PainDETECT  
PainDETECT is a neuropathic pain screening tool that was developed and 
validated in German (Haanpaa, Attal et al. 2011). PainDETECT is an easy-to-apply 
questionnaire that requires no physical examination (Freynhagen, Baron et al. 2006). 
It evaluates seven sensory descriptors and two items related to spatial and temporal 
aspects of pain. Scores range from 0 to 38, and scores 12 and below indicate a 15% or 
less likelihood of having a neuropathic pain component. Scores between 13 and 18 
represent an uncertainty zone where there is a possible neuropathic pain component 
but no measurable likelihood ratio. Finally, scores of 19 and above indicate a greater 
than 90% chance of having neuropathic pain. 
5.6.2 Effects of dorsal root ganglion stimulation on PainDETECT 
PainDETECT was validated as a screening tool to predict the likelihood of a 
neuropathic pain component in chronic pain disorders (Freynhagen, Baron et al. 
2006). A cutoff score of ≥ 19 is thought to indicate a likely neuropathic pain 
component (> 90%). PainDETECT has a sensitivity of 85% and specificity of 80%, 
which is slightly higher in comparison with other screening tool questionnaires and 
has been recommended as a reliable screening tool in neuropathic pain assessment 
guidelines (Haanpaa, Attal et al. 2011). To the best of our knowledge, this is the first 
time PainDETECT is used to assess pain disability associated with DRGS. In the 
present study, mean scores on this measure decreased from 19.7 at M0 to 15.7 at M1 
and 14.5 at M6. This can be interpreted as a trend towards improvement in 
neuropathic pain components with the use of DRGS.  
5.7 Quality of life assessment in neuropathic pain 
 
QoL is broadly assessed as an indirect measure of the effectiveness of a 
treatment for chronic pain. There is a close association between neuropathic pain and 
reduced QoL, even though decreased pain scores may not necessarily lead to better 
QoL. Also, neuropathic pain was shown to have a greater negative impact on QoL 
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than non-neuropathic chronic pain (Jensen, Chodroff et al. 2007, Smith and Torrance 
2012). Generic QoL measures are scales or questionnaires that assess common 
elements of health, well-being and functionality. The Medical Outcomes Survey Short 
Form (SF-36; Brazier, Harper et al. 1992) is recommended by the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) 
(Dworkin, Turk et al. 2005). Recent guidelines also recommended the SF-36 or 
EuroQol five dimensions questionnaire (EQ-5D) to assess QoL in clinical research 
(Haanpaa, Attal et al. 2011). 
5.7.1 Effects of dorsal root ganglion stimulation on quality of life 
We observed an increase in SF-36 mean scores for Vitality, Physical 
Functioning, Pain, Physical Role Functioning, Social Role Functioning and Mental 
Health at M1 and M6 relative to M0. Moreover, just on Pain, scores increased from 
22.5 at M0 to 43.2 at M1 and 52.5 at M6. However, no trend towards improvement 
was detected on two items: General Health Perception and Emotional Role Function. 
The results presented here show a trend towards improvement in six of the 
eight items on the SF-36. Kumar et al. showed a significant score increase on all items 
of the SF-36 questionnaire after 6 months of SCS of the dorsal column in 24 patients 
diagnosed with FBSS (Kumar, Taylor et al. 2007). Rutten et al. also reported 
significant improvement on all items of the SF-36 in a similar group of patients at the 
12 and 24 month follow-ups (Rutten, Komp et al. 2002). To date, no study has 
assessed SF-36 together with DRGS. Liem at al. reported a significant increase in 
QoL as measured by EQ-5D, a similar test, at 6 months (Liem, Russo et al. 2013) and 
at 12 months (Liem, Russo et al. 2015) during the use of DRGS for diverse chronic 
neuropathic pain conditions. Van Buyten et al. also reported significant improvement 
in EQ-5D scores at the 12-month follow-up for CRPS patients treated with DRGS 
(Van Buyten, Smet et al. 2014). Finally, Eldabe et al. reported improvement on EQ-5D 
scores in two patients diagnosed with PLP (Eldabe, Burger et al. 2015).  
In conclusion, the present results show a trend towards improvement in most 
of the SF-36 items. This shows that SF-36 is a valuable tool to assess QoL in patients 
treated with DRGS. 
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5.8 Pain-related disability assessment in neuropathic pain 
Measures of disability are implemented as an indirect evidence of chronic pain 
therapy outcomes. It is well established that chronic neuropathic pain interferes with 
the physical and psychological functioning of patients. Disability is defined as a 
“physical or mental condition that limits a person’s movements, senses or activities” 
(Haanpaa, Attal et al. 2011). Some tools for measuring disability have been 
specifically designed for neuropathic pain. The Brief Pain Inventory (BPI) and PDI 
are recommended for general neuropathic pain conditions (level A) (Haanpaa, Attal 
et al. 2011). PDI is a validated tool that measures an individual’s ability to participate 
in essential life activities (Tait, Pollard et al. 1987, Chibnall and Tait 1994) on a scale 
of 0-70 (higher scores reflect greater disability). PDI assesses seven different life 
dimensions: Family/Home responsibilities, Recreation, Social Activity, Occupation, 
Sexual Behavior, Self Care and Life-Support Activities (Tait, Pollard et al. 1987). 
5.8.1 Effects of dorsal root ganglion stimulation on pain-related disability 
The mean PDI score was 38.5 at M0 and decreased to 22.8 (41%) at M1 and 
18 (54%) at M6, revealing DRGS improved disability over time. In a previous study 
of patients diagnosed with postherpetic neuralgia and acute herpes zoster pain treated 
with SCS, PDI scores decreased significantly after stimulation onset (Harke, 
Gretenkort et al. 2002). In another study of SCS of the dorsal column in FBSS 
patients, the median PDI score dropped from 43 at baseline to 26 (a 40% decrease) at 
the 12-month follow-up and to 28 (a 35% decrease) at the 24-month follow-up 
(Rutten, Komp et al. 2002). Similar findings were also found in a study testing SCS in 
the cervical region, where mean scores dropped from 49.6 at baseline to 28.4 (a 43% 
decrease) at the 12-month follow-up (Deer, Skaribas et al. 2014). No published study 
investigating DRGS has assessed PDI. However, BPI has been implemented as a 
disability measure in some publications showing significant BPI improvement after 
DRGS at 6 months (Liem, Russo et al. 2013) and 1 year (Liem, Russo et al. 2015). 
Finally, a study testing patients diagnosed with CRPS also showed significant 
improvement in BPI scores after 12 months of DRGS onset (Van Buyten, Smet et al. 
2014). 
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In summary, PDI scores decreased, supporting a trend towards improvement 
in disability in our study group. These findings are in accordance with the literature 
and reinforce the use of PDI as a measure of disability in patients under DRGS. 
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6 CONCLUSION 
 
6.1 Laser-evoked potentials 
We found a significant increase in N2/P2 peak-to-peak amplitudes on the 
painful side at M1 and M6 in comparison to M0 (p < .05). On the control non-painful 
side, we detected no visible change in N2/P2 peak-to-peak amplitudes across the three 
time-points. Moreover, when comparing the ratio of the peak-to-peak amplitude 
between painful and non-painful sides at each time-point (M0, M1 and M6), we 
observed a significant decrease of the ratio at M0 only (p < .05). At M1 and M6, both 
ratios were around 1, suggesting LEPs amplitudes were restored to near normal levels.  
6.2 Clinical assessment  
The clinical assessment results showed a clear benefit of using DRGS. NRS 
pain intensity rating scores significantly decreased at M1 and M6 relative to M0 (p < 
.05). As secondary outcomes, PainDETECT, SF-36 and PDI scores also showed a 
trend towards positive outcomes at M1 and M6 relative to M0, except for two items in 
the SF-36 (GHP and ERF).  
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7 SUMMARY 
 
The modern era in neuromodulation for the treatment of pain began after 
Melzack and Wall’s seminal work describing the so-called gate control theory 
(Melzack and Wall 1965). The first application of neuromodulation in a chronic pain 
patient was performed by Shealy in 1967 (Shealy, Mortimer et al. 1967). Since then, 
SCS - traditionally involving the placement of an electrode placed on the dorsal 
column of the spinal cord - has become a valuable method to treat chronic neuropathic 
pain.  
DRGS appeared in 2011 as an interesting new option in neuromodulation for 
chronic neuropathic pain. Even though clinical results addressing DRGS have already 
been published and show encouraging clinical results, limited data concerning 
mechanisms of action have been released to date. This observation highlights the need 
for further investigation into DRGS, e.g. by implementing standardized clinical 
assessment tools or neurophysiological techniques (Forget, Boyer et al. 2015).  
The primary aim of this study was to assess LEPs and to evaluate pain 
intensity changes at 1 and 6 months after DRGS onset in comparison to baseline (no 
stimulation). A secondary aim was to evaluate how DRGS affects different clinical 
measures, as assessed with a neuropathic pain screening tool questionnaire 
(PainDETECT), a generic QoL questionnaire (SF-36), and a questionnaire of 
disability associated with chronic neuropathic pain (PDI). 
Through an open-label study design, we evaluated seven patients (4 men and 3 
women; mean age 50.7 years) diagnosed with unilateral chronic peripheral localized 
neuropathic pain of the groin, knee or leg who were implanted with DRGS electrodes. 
LEPs N2/P2 peak-to-peak amplitude values significantly increased after 1 and 6 
months of DRGS in comparison to baseline (p < .05). The N2/P2 mean values 
increased from 3.7 µV at baseline to 11.3 µV and 10.7 µV at 1 and 6 months, 
respectively. At the end of the sixth month under stimulation, LEPs amplitudes were 
restored to normal values. On the other hand, pain intensity ratings measured through 
NRS scores significantly decreased after 1 and 6 months of DRGS in comparison to 
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baseline (p < .05). The scores dropped from a mean of 7.6 at baseline to 2.1 and 2.2 at 
1 and 6 months, respectively. We also confirmed a trend for improvement in the 
PainDETECT, SF-36, and PDI measures.  
These findings suggest that DRGS increases LEPs amplitude and decreases 
chronic neuropathic pain, resulting in treatment efficacy. We suggest that the 
observed LEPs restoration reflects normalization of pain pathway signal transmission.  
Therefore, a better understanding of the role of the DRG in neuromodulation 
for chronic neuropathic pain will surely impact the field of neuromodulative 
techniques. The present work represents a contribution towards this goal.  
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8 ZUSAMMENFASSUNG 
 
Die moderne Neuromodulations-Ära für die Behandlung von Schmerzen 
begann nach der bahnbrechenden Arbeit von Melzack und Wall, die die sogenannte 
Gate-Steuertheorie (Melzack und Wall 1965) beschrieben. Die erste Anwendung von 
Neuromodulation bei einem chronischen Schmerzpatienten wurde im Jahre 1967 von 
Shealy (Shealy, Mortimer et al. 1967) durchgeführt. Die Rückenmarkstimulation 
(SCS) – traditionell praktiziert durch das Platzieren einer Elektrode am Hinterstrang 
des Rückenmarks – hat sich seitdem als wertvolle Methode etabliert, um chronisch 
neuropathische Schmerzen zu behandeln.  
 
Die Stimulation des Dorsalganglions (DRGS) wurde im Jahr 2011 als eine 
neue interessante Option der Neuromodulation zur Behandlung chronisch 
neuropathischer Schmerzen eingeführt. Obwohl klinische Ergebnisse der 
Dorsalganglienstimulation bereits veröffentlicht wurden und ermutigende Ergebnisse 
zeigen konnten, wurden bislang nur begrenzte Daten bezüglich ihrer 
Wirkungsmechanismen veröffentlicht. Diese Tatsache unterstreicht die 
Notwendigkeit, weitere Untersuchungen bzgl. DRGS durchzuführen, zum Beispiel 
mittels standardisierter klinischer Bewertungsinstrumente oder neurophysiologischer 
Techniken (Forget, Boyer et al. 2015). 
 
Das primäre Ziel dieser Studie war die Untersuchung von Laser evozierten 
Potentialen (LEPs) und die Auswertung von Veränderungen der Schmerzintensität ein 
bzw. sechs Monate nach Beginn der DRGS Behandlung im Vergleich zu 
Ausgangsdaten ohne Stimulation. Ein sekundäres Ziel war die Beurteilung des Effekts 
der Stimulation des Dorsalganglions auf verschiedene klinische Messwerte mittels 
eines Screening-Fragebogens für neuropathische Schmerzen (PainDETECT), eines 
generischen Fragebogens zur Lebensqualität (SF-36) und eines Fragebogens bzgl. der 
Lebensbeeinträchtigungen durch chronische neuropathische Schmerzen (PDI). 
 
Mittels eines Open-Label-Study-Designs werteten wir sieben Patienten mit der 
Diagnose einseitiger chronisch neuropathischer, peripher lokalisierter Schmerzen im 
Bereich der  Leiste, des Knies oder Beines aus, bei denen DRG Elektroden implantiert 
 74 
worden waren. Das mittlere Alter der Studiengruppe war 50.7 Jahre (4 Männer und 3 
Frauen). Die LEPs N2/P2 peak-to-peak Amplitudenwerte waren ein und sechs 
Monate nach Stimulation des Dorsalganglions im Vergleich zum Ausgangswert (p < 
.05) signifikant erhöht. Die N2/P2 Mittelwerte erhöhten sich von 3.7 µV zu Beginn 
der Studie auf 11.3 µV nach einem Monat bzw. auf 10.7 µV nach sechs Monaten. 
Weiterhin hatten sich nach sechs Monaten unter Stimulation die LEPs Amplituden 
wieder auf Normalwerte erholt. Die durch NRS Scores gemessenen Bewertungen der 
Schmerzintensität sind nach einem und sechs Monaten nach Stimulation des DRG im 
Vergleich zu den Ausgangswerten (p < .05) deutlich zurückgegangen. Die Werte 
fielen von einem Mittelwert von 7.6 bei Studienbeginn auf 2.1 nach einem Monat 
bzw. auf 2.2 nach sechs Monaten. Ein Verbesserungstrend bei neuropathischen 
Schmerzkomponenten durch PainDETECT, SF-36 und PDI konnte ebenso aufgezeigt 
werden. 
 
Diese Ergebnisse deuten darauf hin, dass die Stimulation des DRG die LEPs 
peak-to-peak Amplituden erhöht und chronische neuropathische Schmerzen 
verringert, wodurch eine wirksame Behandlung ermöglicht wird. Wir vermuten, dass 
die Wiederherstellung der LEPs Amplituden auf Normalwerte die Normalisierung der 
Schmerzbahnen-Signalübertragung widerspiegelt. 
 
Daher wird das bessere Verständnis für die Rolle des DRG in der 
Neuromodulation bei chronischen neuropathischen Schmerzen mit Sicherheit eine 
Auswirkung auf das Gebiet der neuromodulativen Techniken haben. Die vorliegende 
Arbeit leistet einen Beitrag zu diesem Ziel. 
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